Method of Increasing Bone Toughness and Stiffness and Reducing Fractures

专利摘要:
The present invention relates to a method of increasing the toughness and / or stiffness of bone and / or reducing the likelihood and / or severity of bone fracture by administration of parathyroid hormone. The method can be used to increase the toughness or stiffness of bone at the risk of osteoporosis or at potential or actual traumatic sites such as the gluteal or spine of a patient. The methods of the present invention can reduce the incidence of vertebral fractures, the occurrence of multiple vertebral fractures, the severity of vertebral fractures and / or the occurrence of non-vertebral fractures.
公开号:KR20010072763A
申请号:KR1020017002092
申请日:1999-08-19
公开日:2001-07-31
发明作者:자넷 엠. 호크
申请人:피터 지. 스트링거；일라이 릴리 앤드 캄파니；
IPC主号:

专利说明:

How to increase bone toughness and rigidity and reduce fractures {Method of Increasing Bone Toughness and Stiffness and Reducing Fractures}
[2] Existing agents such as estrogens, bisphosphonates, fluorides, or calcitonins can prevent bone loss by refilling the remodeling space and lead to a 3-5% increase in bone mass, but net bone formation is not significantly stimulated. Bone retention by inhibition of bone metabolic rate may not be sufficient protection against fracture risk in patients who already have significant bone loss. Anabolic agents that primarily increase bone strength by stimulating bone formation can provide better protection against fractures in established osteoporosis patients.
[3] Parathyroid hormone (PTH) is a 84 amino acid product secreted from the mammalian parathyroid gland that regulates serum calcium levels through actions on various tissues, including bone. It is believed that the N-terminal 34 amino acids of bovine and human PTH (PTH (1-34)) are biologically equivalent to hormones of full length. Other amino terminal fragments of PTH (including for example 1-31 and 1-38), or phases of each or all of them activating PTHrP (PTH-associated peptide / protein) or PTH / PTHrP receptor (PTH1 receptor) Fuselage exhibits similar biological effects on bone mass, although the degree of effect may vary.
[4] Studies using various forms of PTH in humans demonstrate anabolic effects on bone and support that it has significant significance for its use in the treatment of osteoporosis and related bone diseases. Significant anabolic effects of PTH on bone have been demonstrated in many animal models and humans, including stimulation of bone formation resulting in a net benefit in bone mass and / or strength.
[5] It is generally believed that PTH administration in human and related animal models has a negative effect on cortical bone. Indeed, the naturally occurring increase in endogenous PTH that occurs in parathyroid dysfunction disorders results in dilution of the cortical bone accompanied by an increase in the binding and mass of the bovine bone. In the last study, when Havers cortical bones (found in humans and higher mammals) were remodeled under the influence of PTH, cortical bone mass and strength decreased while whisker bones would be redistributed so that mass and strength increased. Proposed. For example, in a published clinical study of PTH administration, cortical bone mass decreases after treatment of exogenous PTH, and this finding raised the understanding that treatment of PTH would decrease cortical bone mass and strength. One understanding raised by such studies is that there will be a loss of total skeletal bone mass due to loss of cortical bone. In osteoporosis, the greater loss of the subcetabular bone compared to the loss of cortical bone indicates a high clinical correlation, indicating that mechanical loading is predominantly caused by residual cortical bone. Continued loss of cortical bone will increase the risk of fracture. Therefore, it is important to maintain or increase the residual cortical bone in the treatment of osteoporosis.
[6] Although the sample size was too small for reliable statistical analysis, the effects of PTH on cortical bone in non-human animals such as dogs, ferrets, sheep and monkeys were investigated by harbus remodeling. The intensity of the changes induced by PTH treatment on the mechanical properties of the cortical bone in these animals is unknown. Published studies in rodents show that cortical bone mass increases during administration of PTH, but this benefit is lost after recovery of PTH. However, rodent cortical bone has a structure that is significantly different from the harbors cortical bone and is reshaped by surface adhesion formation and resorption rather than by intracortical remodeling of bone sources. Moreover, technical limitations in biomechanical experiments on rodents' relatively short bones produce artificial measurements when agents such as PTH thicken bones by altering the geometry of the bones. This artificial measure makes it unreliable to investigate the rat cortical bone response in humans or other animals by bone remodeling. Thus, existing data on animals undergoing HARBUS remodeling similarly to humans indicate that PTH may adversely affect cortical bone, resulting in a net loss of bone mass due to depletion of cortical bone.
[7] As a result, there has been public belief that PTH action requires patients to simultaneously or subsequently treat anti-resorptive agents in order to minimize bone loss induced by PTH. In fact, this model has been the basis for many clinical studies in women. For example, PTH has been used in the simultaneous treatment of calcitonin or estrogen in postmenopausal women, or in three clinical studies with GnRH agonists, cinarel, for endometriosis in premenopausal women. The opposing effects of estrogen and PTH on cortical bone metabolic rate make it difficult to observe the effects of PTH alone, especially during the combination treatment of these two agents.
[8] There is a need for a method of using PTH to increase bone strength and stiffness in humans and other animals exhibiting Habers remodeling and to reduce the incidence of bone fractures in these animals. Moreover, there is a need for a method of increasing the quality and amount of cortical bone.
[9] Summary of the Invention
[10] The present invention encompasses methods of increasing the toughness and / or stiffness of bones, in particular the cortical bones, and / or reducing the incidence and / or severity of bones by administering parathyroid hormone. More specifically, the present invention relates to a method of increasing the toughness or rigidity of bone at potential or actual traumatic sites. The increase in bone toughness and / or stiffness can be realized by many methods known to those skilled in the art, such as increasing bone mineral density, increasing bone mineral content, increasing work to failure. In one embodiment, the methods of the present invention reduce the incidence or severity of a vertebral and / or nasal bone fracture. The methods of the present invention can be used to reduce the risk of such fractures or to treat such fractures. In particular, the methods of the present invention can reduce the incidence of vertebral and / or non-vertebral fractures, reduce the severity of vertebral fractures, reduce the incidence of multiple vertebral fractures, and improve bone quality.
[11] The method can increase toughness or stiffness at potential traumatic sites, such as the gluteus or vertebrae of osteoporosis patients, or at other sites with abnormally low bone mass or poor bone structure. The method may also increase bone toughness or stiffness at actual traumatic sites, such as fractures in the gluteus or vertebrae, for example. Preferred subjects of the methods of the invention are women or men at risk or having osteoporosis, preferably postmenopausal women, and are not associated with concurrent hormone replacement therapy (HRT), estrogen or the corresponding therapy, or anti-absorbent therapy. In one embodiment, the patient also absorbs supplements of calcium and / or vitamin D.
[12] Parathyroid hormones, such as the N-terminal amino acids 1-34 of recombinant human parathyroid hormone, may be administered periodically or intermittently. Preferably periodic administration includes administering PTH during at least two remodeling cycles and recovering PTH during at least one remodeling cycle. Moreover, according to the method of the present invention, the increase in toughness and / or stiffness of bone can last for several remodeling cycles or for years after the last administration of parathyroid hormone.
[1] The present invention relates to a method of increasing the toughness and / or stiffness of bone and / or reducing the likelihood and / or severity of bone fracture by administering parathyroid hormone. More specifically, the present invention relates to a method of increasing the toughness and / or stiffness of bone at potential or actual traumatic sites, such as the gluteal or spine of a patient at risk or suffering from osteoporosis. More specifically, the present invention relates to a method of reducing the incidence of vertebral fractures, reducing the incidence of multiple vertebral fractures, reducing the severity of the vertebral fractures, and / or reducing the incidence of non-vertebral fractures.
[13] 1A and 1B show that BMD (bone mineral density) and BMC (bone mineral content) in the femur midshaft (cortical bone) (A) and proximal femur (cavernosal cortical bone) (B) were higher than the control at both doses. Significantly higher in treated animals.
[14] 2A-2D show the effect of PTH on mechanical strength and moment of inertia of the cross section in the cortical bone of the femur midshaft.
[15] 3 illustrates the percentage change in DXA measurements of total bone mineral content in the control and treatment groups.
[16] 4A-4C illustrate the percent change in bone DXA measurements for bone area (A), bone mineral content (B) and bone mineral density (C) in the control and treatment groups of lumbar spine 2-4.
[17] 5A and 5B illustrate the increase in bone mass (A) and bone strength (B) in the lumbar spine of primates treated with parathyroid hormone.
[18] 6A and 6B illustrate the increase in the strength of the femoral bones (A) and the constant strength between the humeral middle bones (B) in primates treated with parathyroid hormone.
[19] 7 illustrates the activation of bone formation rate at the periosteal surface and periosteal surface of the midshaft of the humerus.
[20] FIG. 8 illustrates a histogram analysis of bone volumetric pixel density change in lumbar spine resulting from PTH treatment compared to control. Note the increase in density in the cortical bone compartment after recovery of the PTH treatment.
[21] FIG. 9 illustrates the lumbar BMD increase after 23 months of treatment of patients with 20 μg / kg / day PTH or 40 μg / kg / day PTH compared to placebo treated controls.
[22] 10 illustrates the increase in femur and gluteal BMD after 24 months of treatment of patients with 20 μg / kg / day PTH or 40 μg / kg / day PTH compared to placebo treated controls.
[23] The present invention relates to a method of increasing the toughness and / or stiffness of bone in a subject and / or reducing the occurrence of fractures by administering parathyroid hormone. The method can be used to increase toughness and / or stiffness at potential trauma sites or actual trauma sites. Trauma generally includes fractures, surgical injuries, joint replacements, orthopedic procedures, and the like. Increasing bone toughness and / or stiffness generally includes increasing mineral density of cortical bones, increasing bone strength, increasing resistance to load, and the like. Reducing the incidence of fracture generally includes reducing the likelihood or actual occurrence of fracture in a subject as compared to the untreated control population.
[24] As used herein, ultimate force refers to the maximum force at which a bone specimen is maintained, stiffness refers to the slope of the linear portion of the load deformation curve, and work to failure refers to the area under the load deformation curve before failure. do. Each of these can be measured and calculated by standard methods in the field of bone research. These measures are structural properties that depend on intrinsic material properties and geometry, and are described in Turner CH. Burr DB 1993 "Basic biomechanical measurements of bone: a tutorial." Bone 14: 595-608). Can be measured as if. Ultimate force, stiffness, and failure operations can be generalized to obtain inherent material properties such as ultimate stress, modulus of elasticity, and toughness independent of their size and shape. As used herein, ultimate stress refers to the maximum stress that a specimen can be held in, elastic modulus refers to the inherent stiffness of the material, and toughness refers to resistance to fracture per unit volume. Each of these can be measured by methods known in the art. The femur strength referred to herein can typically be measured using three points in the femoral alley, or the midshaft or four points in the latter case.
[25] Bone trauma
[26] The method of the invention is beneficial to a subject who may or may have trauma in one or more bones. The method may be beneficial for mammalian subjects such as humans, horses, dogs, and cats, especially humans. Bone trauma can be a problem in racehorses and dogs, and also in the case of family pets. Humans can suffer from any of a variety of bone traumas that are strange for example accidents, medical adjustments, diseases or diseases. In young, bone trauma is likely to be due to fractures, medical adjustments to repair fractures, or repair of damaged joints or connective tissue, for example, through athletics. Other types of bone trauma, such as from osteoporosis, degenerative bone disease (such as arthritis or osteoarthritis), gluteal replacement, or secondary diseases associated with the treatment of other systemic diseases (eg, glucocorticoid osteoporosis, burns or organ transplantation) Is very often found in older people.
[27] Preferred subjects include humans, preferably women, at risk of or suffering from osteoporosis. Risk factors for osteoporosis are known in the art, and nutritional factors associated with hypogonadism, osteoporosis (low calcium or vitamin D are most common in men and women, regardless of age, condition, disease, or drug that induces hypogonadism) ), Smoking, alcohol, drugs associated with bone loss (eg, glucocorticoids, thyroxine, heparin, lithium, antispasmodic, etc.), loss of vision to crash, space travel, immobilization, chronic hospitalization, long-term care, and osteoporosis Other systemic diseases associated with an increased risk of dysfunction. Symptoms of the presence of osteoporosis are known in the art and include radiological evidence of one or more vertebral compression fractures, low bone mass (typically one or more standard deviations of the average young normal), and / or non-traumatic fractures. Included.
[28] Osteoporosis can result in, for example, fractures of the vertebrae and / or non-vertebral bones. Examples of vertebral fractures include hip fractures, fractures of the distal forearm, fractures of the proximal humerus, shoulder fractures, radial fractures, osteotomy fractures, humerus fractures, rib fractures, foot fractures, pelvic fractures, or a combination thereof. The methods of the present invention can be used to reduce the risk of such fractures or to treat such fractures. For example, increasing bone strength and / or stiffness in the gluteus, vertebrae, or both can reduce the risk of fracture and assist in the treatment of fractures. Typical women at risk for osteoporosis are menopausal women or premenopausal women with reduced sexual function. Preferred subjects are menopausal women and are not associated with concurrent hormone replacement therapy (HRT), estrogen or the corresponding regimen, or anti-resorptive therapy. The methods of the present invention may be beneficial in any stage of osteoporosis subjects, but are particularly beneficial in early and advanced stages.
[29] The present invention provides methods that are effective in preventing or reducing the occurrence of fractures, particularly in subjects at risk of developing or developing osteoporosis. For example, the present invention can reduce the incidence of vertebral and / or non-vertebral fractures, reduce the severity of vertebral fractures, reduce the incidence of multiple vertebral fractures, improve bone quality, and the like. In another embodiment, the methods of the present invention may be beneficial for patients who have a low bone mass or who are at risk for future multiple skeletal fractures, such as patients who may rapidly develop osteoporosis.
[30] Other subjects may also be at risk of bone trauma, or may have trauma, and the methods of the present invention may be beneficial. For example, surgical procedures can be expected to result in bone trauma to a wide variety of patients at risk of one or more of the above characterized fractures, or bones at skeletal sites lacking abnormally low bone mass or poor bone structure or minerals. Orthopedic procedures to deal with For example, functional recovery may be improved in accordance with the methods of the present invention following surgical procedures such as joint replacement (eg, knee or gluteal) or vertebral braces, or other procedures to fix bone or skeleton. In addition, the methods of the present invention include surgical replacement of bone at sites of abnormally low bone mass or poor bone structure, including prevention of implant drift and joint replacement in cases requiring osteotomy, reconstruction by tibial reconstruction. It can help recover from orthopedic procedures, including. Other subjects suitable for carrying out the present invention include patients with parathyroid hypoplasia or vertebral vertebrae that are able to progress trauma associated with or resulting from parathyroid hypoplasia or vertebral vertigo.
[31] Bone toughness and rigidity
[32] The method of the present invention reduces the risk of trauma or aids in recovery from trauma by increasing bone toughness, stiffness, or both. In general, the toughness or stiffness of bone results from the mass and strength of the cortical bone, the small bone and the cancellous bone. The methods of the present invention can provide bone toughness, stiffness, mass, and / or strength levels within or above the normal population. Preferably the present invention provides an increased level relative to the level resulting from the trauma or which may cause the risk of trauma. Increased toughness, stiffness, or both, reduce the risk or likelihood of fracture when compared to untreated control populations.
[33] Increasing certain properties of the bone increases the toughness and / or stiffness of the bone. These characteristics include bone mineral density (BMD), bone mineral content (BMC), frequency of activity or bone formation rate, bone marrow count, calculus bone thickness, calculus and other bonds, periosteal and intracortical bone formation, cortical porosity, bone Cross-sectional area and bone mass, load tolerance and / or breakage operations. An increase in one or more of these properties is a desirable achievement of the method of the present invention.
[34] Reduction of certain bone properties, such as bone marrow space and modulus, increases bone toughness and / or stiffness. In general, younger bones (greater toughness and rigidity) have smaller microcrystals than those of older bones. Therefore, in general, reducing the size of the bone microcrystals increases the toughness and rigidity of the bone and can reduce the occurrence of fractures. In addition, maturing the bone microcrystals can provide the bone with additional desirable properties, including increased bone toughness and rigidity, and can reduce the incidence of fractures. Reduction of one or more of these properties is a desirable achievement of the method of the present invention.
[35] The method of the present invention is effective to increase the toughness and / or stiffness of any of several bones. For example, the method can increase the toughness and / or stiffness of bones, including gluteal bones such as iliac bone, leg bones such as femurs, bones derived from the spinal cord such as vertebrae, arms such as distal forearm or proximal humerus. . This increase in toughness and / or stiffness can be found ubiquitous throughout the bone or in certain parts of the bone. For example, the toughness and / or stiffness of the femur can be increased by increasing the toughness and / or stiffness of the femoral or femur of the femur. The toughness and / or stiffness of the gluteal can be increased by increasing the toughness and / or stiffness of the iliac crest or iliac crest. The toughness and / or stiffness of the vertebrae can be increased by increasing the toughness and / or stiffness of the vertebral roots, the vertebral discs, or the vertebral bodies. It is advantageously effective for the vertebrae in certain parts of the spinal cord, such as the cervical, thoracic, lumbar, sacral and / or lumbar spines. Preferably at least one central thoracic and / or upper lumbar vertebrae.
[36] An increase in toughness and / or stiffness can be found predominantly in each bone type, or in one type of bone. Types of bone include spongy bone (spongy bone, small bone, or lamellar bone) and dense bone (cortical or dense) and fractured bone. The method of the present invention preferably increases toughness and / or stiffness through the effect on spongy bone and cortical bone, or on cortical bone alone. The trabecular bone to which connective tissue is attached can also be toughened and / or rigidized by the present method. For example, it is advantageous to provide additional toughness at the site of attachment to the ligaments, tendons and / or muscles.
[37] In another aspect of the invention, increasing toughness or stiffness can reduce the occurrence of fractures. In this regard, an increase in toughness or stiffness may include reduced incidence of a vertebral fracture, reduced incidence of severe fractures, reduced incidence of intermediate fractures, reduced incidence of non-vertebral fractures, reduced incidence of multiple fractures, or a combination thereof. .
[38] Parathyroid hormone
[39] The compositions and solutions can incorporate parathyroid hormone in the form of 84 amino acids in full length as the active ingredient, in particular human form of hPTH (1-84) obtained by peptide synthesis or extraction from human body fluids. See, for example, US Pat. No. 5,208,041, which is incorporated herein by reference. The amino acid sequence of hPTH (1-84) has been reported in Kimura et al. (Biochem. Biophys. Res. Comm., 114 (2): 493).
[40] The composition or solution also contains human PTH as an active ingredient, or a rat having human PTH activity as measured in an ovarian isolated rat model of osteoporosis reported in Kimmel et al. (Endocrinology, 1993, 32 (4): 1577), Fragments or variants of fragments of porcine or bovine PTH can be introduced.
[41] Parathyroid hormone fragments are preferably such as PTH (1-28), PTH (1-31), PTH (1-34), PTH (1-37), PTH (1-38) and PTH (1-41). Introduce at least the first 28 N-terminal residues. Another form of PTH variant is leucine of methionine residues at positions 8 and / or 18, or trypsin such as substitution with hydrophobic amino acids to enhance PTH stability against oxidation and amino acids histidines in the 25-27 region One to five amino acid substituents can be introduced that enhance PTH stability and half-life, such as substitutions with non-sensitive amino acids or other amino acids that enhance PTH stability. Other suitable forms of PTH may include PTHrP, PTHrP (1-34), PTHrP (1-36) and homologues of PTH or PTHrP that activate the PTH1 receptor. These forms of PTH are included in the term "parathyroid hormone" as generally used herein. The hormone may be obtained by known recombinant or synthetic methods such as those described in US Pat. Nos. 4,086,196 and 5,556,940, which are incorporated herein by reference.
[42] Preferred hormone is human PTH (1-34), also known as teriparatide. Stabilized solutions of human PTH (1-34), such as recombinant human PTH (1-34) (rhPTH (1-34)) that can be used in the present methods are described in US Patent Application No. 60 / 069,075, which is incorporated herein by reference. Described in Crystalline forms of human PTH (1-34) that can be used in the method are described in US patent application Ser. No. 60 / 069,875, which is incorporated herein by reference.
[43] Administration of parathyroid hormone
[44] Parathyroid hormones can be administered parenterally, preferably by subcutaneous infusion, typically by methods and formulations known in the art. Stabilized formulations of human PTH (1-34) that can be advantageously used in the method are described in US patent application Ser. No. 60 / 069,075, which is incorporated herein by reference. The patent application also describes many formulations for the storage and administration of parathyroid hormone. Stabilized solutions of parathyroid hormones may include stabilizers, buffers, preservatives, and the like.
[45] Stabilizers to be incorporated into the present solutions or compositions include saccharides, preferably monosaccharides or disaccharides such as glucose, trehalose, raffinose or sucrose; For example, polyols containing sugar alcohols such as mannitol, sorbitol or inositol, and polyhydric alcohols such as glycerin or propylene glycol, or mixtures thereof. Preferred polyols are mannitol or propylene glycol. The concentration of the polyol may range from about 1 to about 20 weight percent, preferably about 3 to 10 weight percent of the total solution.
[46] The buffer used in the solution or composition of the present invention is pharmaceutically acceptable and may be any acid or salt combination capable of maintaining an aqueous solution in the range of pH 3 to 7, preferably pH 3-6. Useful buffer systems are, for example, acetate, tartrate or citrate sources. Preferred buffer systems are acetate or tartrate sources, most preferably acetate sources. The concentration of the buffer may range from about 2 mM to about 500 mM, preferably from about 2 mM to 100 mM.
[47] Stabilized solutions or compositions of the present invention may also include parenterally acceptable preservatives. Such preservatives include, for example, cresol, benzyl alcohol, phenol, benzalkonium chloride, benzethonium chloride, chlorobutanol, phenylethyl alcohol, methyl paraben, propyl paraben, thimerosal and phenylmercury nitrate and acetate . Preferred preservatives are m-cresol or benzyl alcohol, most preferably m-cresol. The amount of preservative used may range from about 0.1 to about 2 weight percent of the total solution, preferably from about 0.3 to about 1.0 weight percent.
[48] Thus, the stabilized teriparatide solution also contains mannitol, acetate and m-cresol and may have a predetermined pot life of at least 15 months at 5 ° C.
[49] The parathyroid hormone composition may be provided in the form of a powder containing up to 2% by weight of water produced by lyophilizing a sterile aqueous hormone solution prepared by mixing selected parathyroid hormones, buffers and stabilizers as described above if desired. . Particularly useful as buffers when preparing lyophilized powders are tartrate sources. Particularly useful stabilizers are glycine, sucrose, trehalose and raffinose.
[50] In addition, parathyroid hormones may be formulated with conventional buffers and excipients used in the art to stabilize and solubilize proteins for parenteral administration. Pharmaceutical carriers and formulations thereof recognized in the art are described in Martin ("Remington's Pharmaceutical Science," 15th Ed .; Mack Publishing Co., Easton (1975)). Parathyroid hormone can also be delivered through the lungs, mouth, and nose by suppositories or oral formulations.
[51] The parathyroid hormone is formulated to administer a dosage effective to increase the toughness and / or stiffness of the bones of one or more subjects, and to reduce the likelihood and / or severity of bone fractures. Preferably, the effective dosage provides an improvement in cortical bone structure, mass and / or strength. Preferably, the effective dose reduces the incidence of a vertebral fracture, reduces the incidence of multiple vertebral fractures, reduces the severity of a vertebral fracture and / or reduces the incidence of a non-vertebral fracture. Preferably, the subject receiving parathyroid hormone also receives an effective dose of calcium and vitamin D, which may enhance the effect of the hormone. An effective dosage of parathyroid hormone may be from about 10 to about 40 μg / kg / day, especially in humans, but typically at least about 5 μg / kg / day or more, particularly to achieve increased toughness or stiffness in the cortical bone or Or an amount effective to reduce the incidence of fractures. Parathyroid hypoplasia subjects may require additional or high doses of parathyroid hormone, which subjects also require supplemental therapy of hormones. Dosages necessary for supplemental therapy in hypothyroidism are known in the art. In certain cases, the relevant effects of PTH can be observed even at doses less than about 5 μg / kg / day, or less than about 1 μg / kg / day.
[52] The hormone may be regularly (e.g., daily or once a week), intermittently (e.g., irregularly for one day or week), or periodically (e.g., for days or weeks) Then, for a period of time without administration). Preferably, PTH is administered once daily for 1-7 days for a period of 3 months to 3 years in osteoporosis patients. Preferably, the periodic administration includes administering parathyroid hormone during at least two remodeling cycles and recovering parathyroid hormone during at least one remodeling cycle. Another preferred regimen for periodic administration includes administering parathyroid hormone for at least about 12 to about 24 months and withdrawing parathyroid hormone for at least 6 months. Typically, the benefit of administration of parathyroid hormone remains after the administration period. The benefits of several months of administration can be maintained without further administration for one or two years or more.
[53] Use of formulations of parathyroid hormone
[54] The present invention also includes the present pharmaceutical compositions and includes kits for use in the methods of the present invention. The kit may comprise a vial containing the formulation of the invention and a suitable carrier in a dry or liquid form. The kit also includes instructions for use and administration of the compound in the form of a label on the vial and / or in the insert in a box in which the vial is packaged. The directive may also be printed on the box in which the vial is packaged. The directive includes information such as sufficient dosage and administration information to allow the practitioner to administer the drug. Practitioners are expected to include all doctors, nurses or professionals who can administer the drug.
[55] The invention also relates to pharmaceutical compositions comprising formulations of one or more parathyroid hormones such as human PTH (1-84) or human PTH (1-34) suitable for parenteral administration. In accordance with the present invention, formulations of one or more parathyroid hormones such as human PTH (1-84) or human PTH (1-34) may be used to prepare a composition or medicament suitable for administration by parenteral administration. The invention also relates to a method for preparing a composition comprising a formulation of one or more parathyroid hormones such as human PTH (1-84) or human PTH (1-34) in a form suitable for parenteral administration. For example, liquid or solid formulations can be prepared in a number of ways using conventional techniques. Liquid formulations may be formulated at a suitable pH such as water comprising one or more parathyroid hormones, such as human PTH (1-84) or human PTH (1-34), with a buffer or other excipient to form one of the stabilized solutions described above. It can be prepared by dissolving in a suitable solvent.
[56] The following examples are illustrative of the invention and are not intended to be limiting.
[57] <Example 1>
[58] Increased Bone Strength and Density Following Administration of rhPTH (1-34) to Rabbits
[59] Experimental procedure
[60] One intact New Zealand White Rabbit (HRP Inc. Denver, Pa.), Weighing 3.25 to 3.75 kg, of 9 months old, one of the smallest animals that form bone sources by intracortical remodeling, averaged in groups of six each Classified as body weight group. Both test groups were infused with biosynthetic PTH (1-34) at doses of 10 or 40 μg / ml / kg / day. The control group was injected with 1.0 ml / kg / day of acidified 0.9 M saline containing 2% heat inactivated rabbit serum. PTH (1-34) or vehicle was injected subcutaneously once daily for five days each week for 140 days. Rabbits were fed rabbit laboratory food containing 0.5% Ca and 0.41% P and watered from time to time.
[61] The choice of dosage was (1) after a single infusion of 100 μg / kg PTH (1-34), serum calcium vapoured and did not return to baseline by 24 hours, whereas after a single dose of 50 μg / kg serum Calcium returns to baseline within 24 hours, (2) repeated infusion of 20 μg / kg PTH (1-34) results in a transient increase in serum calcium and returns to baseline within 6 to 24 hours, (3) 5 PTH (1-34) of μg / kg or less was based on a series of preliminary studies showing no alteration of the tissue morphology of the bone surface.
[62] Duplicate Alizarin labeled (Sigma, Santa Lewis) groups were generated at 20 mg / kg intramuscularly on days 55 and 63, and double calcein labeled (Sigma, Santa Lewis) groups at 5 mg / kg subcutaneous on days 15 and 7 After producing, sacrifice was made. About 3 to 6 hours after the last injection, rabbits were anesthetized with CO ₂ in random order, collected into the blood by heart puncture, and killed by intraperitoneal injection of sodium pentobarbital (100 mg / kg). Both the right humerus, femur, lumbar spine (L3-L5) and right tibia were removed.
[63] Blood chemistry
[64] Computerized multichannel serometry measured serum calcium, phosphate, alkaline phosphatase, creatinine and urea nitrogen.
[65] Organization type measurement
[66] Tissue morphometric measurements were performed on the cortical bone of the tibia midshaft and the cavernous bone of L3. After sacrifice, these bones were removed from each animal and fixed in 10% neutral buffered formalin for 24 hours. The tissues were dehydrated in a series of gradient alcohols (70-100%, 2 changes per gradient, 4 hours each under vacuum). Samples were placed in xylene and infiltrated methylmethacrylate with a 2 hour / step and 24 hour infiltration schedule under a 20 psi vacuum in a Shandon Hypercenter automated processor (Shandon Lipshaw, Pittsburgh, PA). Samples were embedded with 0.2% initiator (Delaware Diamond Naives, Wilmington, Delaware) in 2% DDK-Plast. A cross section of the tibia was cut to 80 μm using a diamond wire saw (Delaware Diamond Naives, Inc., Delaware) and stained with Goldner tricolor staining. An undyed cross section about 80 μm thick was processed for dynamic tissue morphometry of the fluorescent pigment label. The sagittal cross sections of L3 were cut to 5 μm with a Lerickert-Yellow 2050 microtome (Magic Scientific Inc., Dexter, Mich.) And stained with McNeil four-color staining or for dynamic histomorphometry.
[67] Tissue morphology measurements were performed at 150 × magnification using a Nikon fluorescence microscope (Optipot, Nikon, Japan) and a semi-automatic digital system (BioQuant IV, R & M Biometrics, Nashville, Tennessee). Bone formation and resorption in the periosteum, intracortical and intracortical cortex were measured along the entire cross-sectional area of the medial interosseous region of the tibia. Measurements on the cavernous bone were made within an area of 6 mm ² at the center of the lumbar spine 0.5 mm from the edge around the cortical cortex. The nomenclature is based on the ASBMR Committee on Tissue Nomenclature (Parfitt AM, Drezner MK, Florieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 "Bone histomorphometry: standardization of nomenclature, symbols, and units. the ASBMR Histomorphometry Nomenclature Committee ". J. Bone Miner. Res. 2: 595-610). Dynamic measures were measured based on calcein labeling.
[68] Bone mass measurement
[69] Midshafts of the femur and fourth lumbar spine in 50% ethanol / saline were scanned by cross-section by quantitative computed tomography (QCT or pQCT) using 960A pQCT, and Dihite software version 5.1 (Norland / Stratec, Wisconsin). Primary paint actinson). Total tissue including volume bone mineral density (vBMD, mg / cm ³ ), cross-sectional area (X-area, mm ² ), and bone mineral content (BMC, mg) using a volumetric pixel size of 148 × 148 × 1200 μm. The scale was measured. The volume can be calculated by multiplying the X-area by the piece thickness of 1.2 mm. The entire femoral alley of the excised femur in a 50% ethanol, saline bath was scanned using a peripheral dual energy absorbometer (pDEXA, Norland / Stratec). Specifically, the apparent bone mineral density (aBMD, g / cm ² ), projected area (cm ² ) and bone mineral content (BMC, g) were measured using an injection step of 0.5 × 1.0 mm and a threshold of 0.04.
[70] Biomechanical Experiment
[71] The mechanical properties of the bones were measured in the body of the right femoral midshaft and L5. The bones were excised, the connective tissue removed, wrapped in gauze dipped in isotonic saline and frozen at -20 ° C until experimental. Prior to the experiment, the samples were thawed at room temperature for 1-2 hours. All samples were tested for failures using a MTS 810 Sustainability Force Test Instrument (MTS, Minneapolis, Minnesota) in a 37 ° C. circulating water bath. Load-strain curves were recorded using an HP 7090A measurement plotting system (Hewlett Packard, Camas, Wash.). Extreme forces (maximum force at which the sample is held), stiffness (slope of the linear portion of the load-strain curve) and breakage operations (area under the load-strain curve before failure) are digital systems (Jandell Scientific, Cote Madera, CA) ) Was measured. These measures are structural properties that depend on intrinsic material properties and geometry (Turner CH, Burr DB 1993 "Basic biomechanical measurements of bone: a tutorial." Bone 14: 595-608). The data were standardized to obtain unique material properties such as ultimate stress independent of size and shape (maximum stress at which sample is maintained), modulus of elasticity (material intrinsic strength), and toughness (resistance to fracture per unit volume).
[72] Femur strength was measured on the midshaft using 3-point bending. The femur was placed in a fixture with the anterior side facing the load. The load was applied at the midpoint between two supports located 54 mm apart. The load cell was moved at a rate of 1 mm / second until breakage was observed. The flexural ultimate stress was calculated from the ultimate force by Equation 1 to normalize the data obtained from the load strain curves.
[73] σ _f = FuLr / 8I
[74] Where σ _f is the bending fracture stress, Fu is the ultimate force, L is the length between the supports, r is the radius in the forward-rear direction, and I is the moment of inertia. The moment of inertia was calculated on the assumption that the femur cross section was elliptical.
[75] The average cortical thickness was calculated from thickness measurements made in each quadrant of the femur section using each pair of digital sideviewers (Mitsutoyo, Japan) with 0.01 mm accuracy with ± 0.005 mm accuracy.
[76] Elastic modulus (E _f ) of the femur was calculated using Equation 2 below.
[77] E _f = (stiffness) * (L ³ / 48I)
[78] Toughness (toughness _f ) of the femur was also calculated using Equation 3 below.
[79] Toughness _f = 3 * (breaking) * r ² / LI
[80] For mechanical experiments of the fifth lumbar vertebra (L5), both end plates of the vertebral body were cut in parallel using a Buhel Isommet low speed saw (Buhel Elti., Ivanston, Illinois). After back ablation, the mechanical strength of L5 was measured under compression. In order to correct the non-parallel alignment of the vertebral surface, the compression load was applied by stroke control at a crosshead speed of 1 mm / sec through the pivot platen. In order to normalize the data obtained from the load strain curve and evaluate the intrinsic material properties independent of the bone geometry, the ultimate stress was calculated by dividing the ultimate force over the entire cross section.
[81] The cross-sectional area (CSA) was calculated by the following equation.
[82] CSA = πab / 4
[83] Wherein a and b are the widths in the front-rear and center-side directions, respectively.
[84] Elastic modulus (E _v ) of the vertebra was calculated by the following equation (5).
[85] E _v = (rigid) / (CSA / h)
[86] Where h is the head-tail height of the vertebral body.
[87] The toughness of the vertebrae (toughness _v ) was calculated by the following equation.
[88] Toughness _v = (breakage) / (CSA * h)
[89] Sound wave microscopy
[90] A diamond wire saw was used to cut a 500 μm thick cross section from the middle bone of the right humerus. The apparent thickness of each specimen was measured at 1 μm resolution using a micrometer (Mitsutoyo, Japan). Scanning sound microscopy (Honegawa K, Turner CH, Recker RR, Wu E, Burr DB 1995 "Elastic properties of osteoporotic bone measured by scanning acoustic microscopy" .Bone 16: 85-90) UH3, Japan Olympos) was used to measure sound velocity. This technique can be used to measure detailed intrinsic mechanical properties at selected lesion points. A 50 MHz transducer (V-390, Panametrics, Waltham, Mass.) Was used to generate sound wave of wave-resonance pattern. A 50 MHz lens produced an acoustic beam of approximately 60 μm diameter. The specimen was fixed to the bottom of the chamber filled with water at a constant temperature (22 ° C.). The delay time between the sound waves reflected from the top of the sample and the sound waves reflected from the bottom of the sample was measured using a digital oscilloscope (TDS 620, Technics, Beaverton, Oregon). The delay time was measured in five different areas where each site is at least 300 μm from each other in the anterior cortex of the humerus. The sound velocity was calculated twice by dividing the sample thickness by the average delay time. A balance (AJ100, METTLER INSTRUMENTS, Heightstown, NJ) was used to determine wet weight (Ww) and deposit weight (Ws) in 100% ethyl alcohol. Wet density (ρ) was calculated using the Archimedes principle of Equation 7 below.
[91] ρ = {Ww / (Ww-Ws)} * ρETOH
[92] Where ρETOH is the density of the alcohol (0.789 g / cm ³ ). Assuming that the acoustic path in the bone is uniform, the elastic modulus (C), which represents the intrinsic strength of the specimen, is calculated by the following equation (8).
[93] C = ρ * V ²
[94] Where p is the wet density and v is the sound velocity.
[95] Statistical analysis
[96] Bartlett analysis was used to examine the uniformity of the deviations. If the deviation was uniform, Fisher's one-way ANOVA of PLSD test for post-hawk comparison was applied. If the deviation was non-uniform, the Krukal Wallis non-scale analysis of the deviations was applied in addition to the post-hawk analysis using the U-test of Mangaitni. The statistical significance level was p <0.05. The results are expressed as mean ± SEM.
[97] result
[98] Body weight and biochemistry
[99] Rabbits treated with vehicle PTH (1-34) at 10 mg / kg / day observed a slight increase in body weight over 140 days. Rabbits given PTH (1-34) at 40 μg / kg / day showed a small decrease in body weight of 51 g, which represented 1.4 ± 1.6% body weight loss during the experiment (Table 1). Serum measurements were within normal physiological responses in rabbits, although small increases in serum calcium and urea nitrogen were observed. Serum alkaline phosphatase was doubled at high PTH (1-34) doses (Table 2).
[100] Effect of PTH (1-34) on Body WeightControlPTH (1-34) 10 μg / kg / dayPTH (1-34) 40 μg / kg / day Initial weight (kg) Final weight (kg) Weight gain (kg)3.43 ± 0.083.70 ± 0.050.26 ± 0.093.42 ± 0.083.51 ± 0.050.09 ± 0.053.42 ± 0.083.37 ± 0.10-0.05 ± 0.05 * Data are expressed as mean ± SEM for 6 rabbits per group. * P <0.05 compared to control.
[101] Effect of PTH (1-34) on Serum ChemistryControlPTH (1-34) 10 μg / kg / dayPTH (1-34) 40 μg / kg / day Calcium (mg / dl) Phosphate (mg / dl) Alkali phosphatase (iu / l) Creatinine (mg / dl) Urea nitrogen (mg / dl)12.1 ± 0.34.7 ± 0.224.7 ± 4.11.9 ± 0.118.3 ± 0.312.6 ± 0.24.7 ± 0.241.0 ± 8.11.6 ± 0.118.1 ± 0.813.5 ± 0.3 * 5.5 ± 0.349.8 ± 7.1 * 1.8 ± 0.123.9 ± 1.9 Data are expressed as mean ± SEM for 6 rabbits per group. * P <0.05 compared to control.
[102] Organization type measurement
[103] Bone formation on the periosteal (Ps.MS/BS) and intracortical (Ec.MS/BS) surfaces of the tibial midshaft was increased in the PTH (1-34) treated group (Table 3). Ps.MS/BS in the high dose group was significantly larger in the other two groups (p <0.001), and Ec.MS/BS in the high dose group was significantly larger than in the control group (p <0.05). Consistent with the increase in serum alkaline phosphatase, the rate of bone formation on each surface (Ps.MS/BS and Ec.BFR / BS) was significantly higher in the high dose group than the other two groups (p <0.05). The mineral adhesion rate (MAR) did not change on the periosteum or intracortical envelope.
[104] Intracortically, the number of resorption sites (Rs.N / Ct.Ar) in rabbits injected with 40 μg / kg / day of PTH (1-34) was significantly greater than that of the other two groups (p <7). 0.05) (Table 4). In addition, the number of labeled bone sources (L.On.N / Ct.Ar) in rabbits injected with PTH (1-34) at 40 μg / kg / day was significantly increased compared to the other two groups (p for control). <0.01, p <0.05 for 10 μg / kg / day). MAR was significantly greater in both treatment groups than the control group (p <0.01), but there was no significant difference between the PTH-treated groups. Bone formation rate (BFR / BV) and activation frequency (Ac.F) were increased in both dose groups (p <0.05 and p <0.01, respectively).
[105] Bone area (B.Ar) was increased in both dose groups, but only significant differences were found between the high dose group and the control group (p <0.01). Bone marrow area (Ma.Ar) decreased after treatment, but there was no significant difference between the three groups. However, the cortical area (Ct.Ar) in the high dose group was significantly larger than the other two groups (p <0.0001 for the control group and p <0.05 for the low dose group). In addition, Ct.Ar in the low dose group was significantly higher than the control group (p <0.05). Similar results were observed for% Ct.Ar.
[106] Cortical porosity (Ct.Po) in rabbits injected with 10 μg / kg / day of PTH (1-34) was twice that of the control (p <0.05), while 40 μg / kg / day of PTH (1-34) ) Was 6-fold higher (p <0.01) in the rabbits injected with). However, the pores are located in the intracortical compartment, and PTH also increases the cortical bone area in line with the increase in the moment of inertia of the cross section, so it is unlikely to contribute to the biomechanical strength within such locations.
[107] Effect of PTH (1-34) on Periosteal and Intracortical Bone Remodeling of Tibia Midshaft MeasureAbbreviationControlPTH (1-34) 10 μg / kg / dayPTH (1-34) 40 μg / kg / day Intracortical bone source Intracortical bone source Thickness Periosteal mineral adhesion rate Cortical mineral attachment rate Periosteal mineralization Surface Intracortical mineralization Surface periosteal bone formation rate Cortical bone formation rateEc.OS / BS (%) Ec.O.Th (μm) Ps.MAR (μm / day) Ec.MAR (μm / day) Ps.MS/BS (%) Ec.MS/BS (%) Ps. BFR / BS (μm ³ / μm ² /year)Ec.BFR/BS (μm ³ / μm ² / year)8.8 ± 6.07.4 ± 2.40.33 ± 0.171.33 ± 0.223.8 ± 1.926.4 ± 6.60.02 ± 0.020.40 ± 0.1013.7 ± 10.53.7 ± 2.30.38 ± 0.080.79 ± 0.168.2 ± 2.132.6 ± 8.20.03 ± 0.010.31 ± 0.1020.2 ± 5.88.1 ± 0.90.66 ± 0.141.32 ± 0.1522.3 ± 2.7 * ‡ 57.7 ± 10.4 * 0.16 ± 0.05 * ‡ 0.72 ± 0.12 * ‡ Data are expressed as mean ± SEM for 6 rabbits per group. * P <0.05 compared to control. ‡ p <0.05 compared to PTH (1-34) 10 μg / kg / day
[108] Effect of PTH (1-34) on Intracortical Bone Remodeling of Tibia Midshaft MeasureAbbreviationControlPTH (1-34) 10 μg / kg / dayPTH (1-34) 40 μg / kg / day Resorption river labeled bone source bone source thickness inorganic attachment rate bone formation rate activation frequency bone area bone marrow area cortex area% cortex areaRs.N / Ct.Ar (# / mm ² ) L.On.N / Ct.Ar (# / mm ² ) O.Th (μm) MAR (μm / day) BFR / BV (% / year) Ac. F (# / mm ² / year) B.Ar (mm ² ) Ma.Ar (mm ² ) Ct.Ar (mm ² )% Ct.Ar (%)0.014 ± 0.0130.011 ± 0.0064.92 ± 0.591.19 ± 0.200.5 ± 0.31.8 ± 1.029.1 ± 1.312.7 ± 0.716.4 ± 0.956.4 ± 1.50.013 ± 0.0040.027 ± 0.0065.42 ± 0.301.56 ± 0.13 * 8.5 ± 2.9 * 15.1 ± 5.0 * 33.3 ± 1.911.9 ± 1.021.3 ± 1.2 * 64.2 ± 1.6 *0.097 ± 0.036 * ‡ 0.215 ± 0.094 * ‡ 5.16 ± 0.271.60 ± 0.12 * 21.4 ± 3.8 * 43.8 ± 10.5 * ‡ 37.8 ± 2.7 * 10.7 ± 1.027.1 ± 2.0 * ‡ 71.6 ± 1.5 * ‡ Data are expressed as mean ± SEM for 6 rabbits per group. * P <0.05 compared to control. ‡ p <0.05 compared to PTH (1-34) 10 μg / kg / day
[109] Effect of PTH (1-34) on the Spongy Bone Remodeling of the Third Lumbar Bone MeasureAbbreviationControlPTH (1-34) 10 μg / kg / dayPTH (1-34) 40 μg / kg / day Bone volume Small bone thickness Thickness Cortical osteoclast Surface Osteoblastic surface Osteoblastic surface Osteoplasm thickness Osteoskeleton Volume Inorganic attachment rate Inorganicization Surface bone formation rateBV / TV (%) Tb.Th (μm) ES / BS (%) Oc.S / BS (%) OS / BS (%) Ob.S / BS (%) O.Th (μm) OV / TV ( %) MAR (μm / day) MS / BS (%) BFR / BS (μm ³ / μm ² / year)27.5 ± 1.4124.8 ± 7.30.5 ± 0.30.4 ± 0.25.2 ± 1.31.4 ± 0.65.2 ± 0.50.10 ± 0.021.3 ± 0.24.4 ± 1.419.7 ± 5.330.5 ± 3.4147.4 ± 12.71.4 ± 0.30.9 ± 0.37.2 ± 1.21.3 ± 0.65.3 ± 0.50.13 ± 0.031.5 ± 0.17.4 ± 1.938.5 ± 8.927.9 ± 3.2126.4 ± 13.72.6 ± 0.7 * 1.3 ± 0.327.7 ± 3.8 * ‡ 15.3 ± 5.6 * ‡ 4.4 ± 0.20.46 ± 0.07 * ‡ 1.7 ± 0.124.2 ± 1.5 * ‡ 153.0 ± 15.6 * ‡ Data are expressed as mean ± SEM for 6 rabbits per group. * P <0.05 compared to control. ‡ p <0.05 compared to PTH (1-34) 10 μg / kg / day
[110] In cavernous bone, most formation measures (OS / BS, Ob.S / BS, OV / TV and MS / BS) increased with PTH (1-34) treatment (Table 5). Rabbits injected with 40 μg / kg / day of PTH (1-34) were significantly larger than the other two groups (all measures p <0.01 for both control and 10 μg / kg / day). Bone formation rate (BFR / BS) was also significantly increased in rabbits injected with 40 μg / kg / day of PTH (1-34) compared to the other two groups (for both control and 10 μg / kg / day groups). p <0.0001). Resorption (ES / BS and Oc.S / BS) increased in both PTH (1-34) treated groups, but the corroded surface (ES / BS) was significantly greater than the control group in the high dose group (p <0.001). ). There was no difference in bone thickness (O.Th) between the three groups. Despite evidence of accelerated bone metabolic rate, the bone volume (BV / TV) of the fraction did not change after PTH (1-34) treatment. Tunnel resorption and subperipheral fibrosis were not observed in any group.
[111] Bone mass measurement
[112] The vBMD and BMC in the midshaft of the femur as assessed by pQCT in the 40 μg / kg / day group were significantly higher than the other two groups (p <0.001 in vBMD and p <0.0001 in BMC, low dose group for the control group). P <0.05 in vBMD and p <0.01 in BMC) (FIG. 1A). VBMD and BMC in the 10 μg / kg / day group were also significantly higher than the control (p <0.05 in both vBMD and BMC). The bone area of the midshaft of the femur was also increased dose-dependently, but significantly increased only at 40 μg / kg / day (p <0.05).
[113] The dose-dependently increased aBMD and BMC in the proximal femur measured by dual X-ray absorptiometry (DXA or pDXA). There was a significant difference in both aBMD and BMC in the control and 10 μg / kg / day group (p <0.05) as well as between the control and 40 μg / kg / day group (p <0.001) (FIG. 1B). No significant difference in bone area was found between the three groups.
[114] Overall, FIG. 1 shows that BMD (bone mineral density) and BMC (bone mineral content) in the femur midshaft (cortical bone) (A) and proximal femur (sponge + cortical bone) (B) compared to the control at both doses. Significantly higher in treated animals. Cortical bone area in the femoral midshaft in rabbits treated at high doses was significantly larger than in the control group. No significant differences were found between the groups in the bone area of the proximal femur. Data are expressed as mean ± SEM. * P <0.05 compared to control. ‡ p <0.05 compared to PTH 10 μg / kg / day.
[115] There was no significant difference between these three groups in vBMD, BMC or bone area of lumbar spine (L4) as assessed by pQCT.
[116] Biomechanical Experiment
[117] Structural properties of the femur midshaft, such as extreme force, stiffness and breakage work, increased dose-dependently (FIG. 2). 2 shows the effect of PTH on mechanical strength and moment of inertia (CSMI) of the cross section in the cortical bone of the femur midshaft. Structural mechanical properties (open bar) and CSMI were significantly increased in the high dose group, while stiffness was significantly increased in the low dose group. Of the intrinsic material properties (dark bars) only elastic modulus was significantly increased in the low dose group compared to the control. The modulus of elasticity in the high dose group was significantly decreased compared to the low dose group. In Figure 2, the data are presented as mean ± SEM, * indicates p <0.05 when compared to the control and ‡ indicates p <0.05 when compared with 10 μg / kg / day.
[118] In the present study and the results shown in FIG. 2, all measures were significantly higher in rabbits injected with 40 μg / kg / day of PTH (1-34) compared to controls (p <0.01 for extreme force and breakage operations, stiffness). P <0.05). Stiffness in the low dose group was also significantly higher than the control group (p <0.05). Among the intrinsic material properties, only the modulus of elasticity was significantly smaller in rabbits injected with 40 μg / kg / day (p <0.01) than with 10 μg / kg / day.
[119] In lumbar vertebral bodies, no significant difference in mechanical properties was found between the three groups.
[120] Sonic microscope
[121] There was no significant difference in sonic velocity or modulus of elasticity between the three groups.
[122] Review
[123] Cortical bone skeletal response to biosynthetic hPTH (1-34) is associated with both direct and complementary control of biomechanical properties in the long bones of intact mature female rabbits. PTH (1-34) increased bone metabolic rate and cortical porosity, and decreased the material elastic modulus of cortical bone at 40 μg / kg administration. However, the reduced modulus of elasticity is more than compensated for by increased bone deposition on the periosteum and intracortical surface, resulting in significant improvements in the structural strength, stiffness, and breakdown operations of cortical bone in rabbits.
[124] In this study with intact rabbits, spongy bone volume of lumbar spine did not change after PTH (1-34) treatment despite evidence of increased bone metabolic rate. The earlier use as an osteopenia model, the presence of intracortical bone remodeling, and short remodeling periods with rapid growth and early skeletal maturation of rabbits (within 6 to 9 months) to examine the effects of intermittent administration of PTH (1-34) Criteria for rabbit selection as a model for
[125] Rabbits can exhibit wide variations in serum calcium levels (10-16 mg / dl), but these levels are not directly affected by the amount of feeding calcium, which is another benefit of the model. A transient significant increase of approximately 1 mg / ml was recorded in rabbits treated with 40 μg / kg of PTH (1-34), but the actual value was always within the known physiological range.
[126] In the present study, 140 days of biosynthetic hPTH (1-34) increased the rate of bone formation on the periosteum and intracortical surface as well as in the cortical bone. Cortical bone Ac.F increased by 8 × in the low dose group and 20 × in the high dose group. This results in a two-fold increase in cortical bone porosity in the tibia and a six-fold increase in the high dose group. Data from sonic microscopy indicates that the elastic properties of the bone material itself in the humerus are not affected, indicating that the intrinsic cortical bone quality is normal. Therefore, the increased porosity must take into account the slight decrease in the modulus of elasticity, which is a measure of the material properties including space in the cortex.
[127] However, increased cortical porosity may be more than compensated for by a significant increase in MS / BS and BFR / BS on the periosteum and intracortical surface of the midshaft of the tibia in the high dose group, resulting in a significant increase in bone area. This may increase the moment of inertia of the cross section and is proportional to the bending strength of the bone as in the femur midshaft (FIG. 2). As a result of these changes in shape and material properties, the mechanical strength and stiffness between the femoral bones can be improved as compared to the control, thereby offsetting potentially poor mechanical effects of increased cortical bone porosity.
[128] conclusion
[129] In conclusion, an increase in bone metabolic rate and cortical bone porosity after PTH (1-34) treatment involves a simultaneous increase in bone at the periosteum and intracortical surface. The combination of these phenomena resulted in an improvement in the toughness ultimate stress, stiffness and breakage work of the femur.
[130] <Example 2>
[131] Increased Bone Strength and Density Following Administration of rhPTH (1-34) to Monkeys
[132] Experimental procedure
[133] Normal
[134] Wild adults (closed growth plates) cynomolgus primates ( Macaca fascicularis ) weighing 2.77 ± 0.03 kg (standard deviation of mean ± mean) [SEM] were used for in vivo studies. Monkeys were quarantined for 3 months, feedings containing 0.3% calcium, 0.3% phosphate, and 250 IU of vitamin D3 / 100g food were started and given a certain amount of fluoride (1 ppm fluoride) from time to time. The calcium content corresponded to 1734 mg calcium / 2000 calories. After 1 month of feeding, animals were grouped into either Sham-operated or ovarian isolated 21 or 22 groups. Subcutaneous infusion of vehicle (false and ovarian control) or rhPTH (1-34), 1 μg / kg (PTH1) or 5 μg / kg (PTH5) was initiated once daily 24 hours after ovarian extraction. Animals were treated for 18 months (PTH1 and PTH5) treatment or 12 months following treatment (PTH1-W and PTH5-W) recovery.
[135] The study group was divided as in Table 6.
[136] Research group for primate research groupAbbreviationEarly monkey (n = 128)Monkey at final analysis (n = 121) False ovary, 18 months vehiclefalsehood2121 Ovarian, 18-month vehicleOVX2220 Ovarian isolated, 18 months 1 μg rhPTH (1-34) / kg / dayPTH12119 Ovarian, 12 months 1 μg rhPTH (1-34) / kg / day, 6 months vehiclePTH1-W2120 Ovarian isolated, 18 months 5 μg rhPTH (1-34) / kg / dayPTH52221 Ovarian, 12 months 5 μg rhPTH (1-34) / kg / day, 6 months vehiclePTH5-W2120
[137] Serum and urine samples were taken at 3 month intervals 24 hours after vehicle or rhPTH (1-34) injection. Sampling at baseline, 7, 11 and 17 months (every 0-240 minutes each time period), the design of the litter samples of five monkeys in each case of the rhPTH (1-34) treated group was used for pharmacodynamics. . Total skeletal and spinal (L-2 and L-4) bone mass at 0 hour and 6 month intervals was assessed using dual energy x-ray absorptiometry (DXA), and peripheral quantitative computerized x-ray tomography ( pQCT) was used to assess bone mass in the midshaft and distal radius and proximal tibia. Iliac specimens were taken at 6 and 15 months for histology. All animals were euthanized 18 months later.
[138] Biomechanical experiments were performed on cortical bone samples mechanically taken in the lumbar L-3 and L-4, femoral, mid-shaft, and femoral bones (measurement defined in Table 7). Conventional static and dynamic histomorphometry was performed on humerus midshaft, lumbar L2, femoral condyle, femoral midshaft, radial midshaft and distal radius (measurement described in Table 11). Initial statistical analysis compared all groups to vehicle treated ovarian isolated controls. The data is suitable for further experimental analysis to investigate dose dependency, recovery effects, interactions between results, and time changes by methods known to those skilled in the art. All assays were performed and measured by methods known in the art.
[139] For certain subjects, cortical bones of the humerus were examined using histomorphometry and polarized Fourier transform infrared microscopy. Fourier transform infrared microscopy was performed by adopting a known method for such a microscope.
[140] 3D Constraint Modeling Study
[141] These studies determined 3D restriction element modeling data on the vertebrae from study monkeys that were PTH administered for 18 months. L-5 vertebrae excised from ovarian extracted (n = 7) and PTH (n = 7) groups in 50% ethanol / saline were 70 × 70 by quantitative computed tomography (QCT, Noland, Wisconsin, Paint Akinson). Scanning was continued in 500 μm steps using μm pixels. Each of the 500 μm cross sections was characterized by volume bone mineral density (BMD, mg / cc), bone mineral content (BMC, mg), cross-sectional area (X-area), spongy bone volume (BV / TV), trabecular bone thickness (Tb.Th) and The degree of binding (nodule density, strut analysis) was analyzed. The pixels in each series of scanning were averaged to produce 490 × 490 × 500 μm volumetric pixels. Nesting consecutive scans and using a "marching cube" algorithm (see, for example, Lawrson and Klein 1987 "Marching cubes a high resolution 3D surface construction algorithm." Computer Graphics 21, 163-169). Three-sided meshes were generated for each bone. A smoothed version of each surface mesh was used to generate a slope mesh for 3D constraint modeling.
[142] From the original volumetric density, the Young's modulus of each slope element and the material properties from the beam of the cortical bone processed from the femur bone of the monkey were derived. Each tetrahedral mesh was rotated to align the bottom surface of each vertebra with the plane. A distributed load of 100 N was applied to the central top surface perpendicular to the bottom surface, and a linear elastic stress analysis was performed on each L-5 model with the bottom surface fixed in the load direction. The resulting axial stress curves were evaluated as BMD distributions and compared between PTH and ovarian extracted. In this interpretation, the density of each volumetric pixel differed depending on the extent to which each volumetric pixel was filled with bone, unlike soft tissue.
[143] result
[144] The difference report in the literature was statistically significant p <0.05. All animals increased 4% to 9% of their initial body weight during the study regardless of treatment.
[145] Serum and Urine Measurements
[146] Serum estradiol levels at 3 and 18 months were below 5 pg / ml in all ovarian monkeys. When the calcium homeostasis was compared to the false control group, the ovarian isolated control group had lower serum calcium and phosphate and 1,25-dihydroxyvitamin D levels, but the endogenous PTH, urine cyclic, measured 24 hours after the last injection. There was no difference in adenosine monophosphate (cAMP), urine calcium, urine creatinine or serum urea nitrogen. rhPTH (1-34) treated animals had lower serum phosphate, lower endogenous PTH, and higher 1,25-dihydroxyvitamin D and urine AMP compared to ovarian isolated. Serum bone formation marker analysis showed that ovarian monkeys had lower serum total alkaline phosphatase (ALP) and osteocalcin compared to the false group, and rhPTH (1-34) recovered levels to false group values. Urine C-telopeptide (CrossLabs) secretion, used as a biochemical marker of bone resorption, was not altered by rhPTH (1-34) compared to ovarian isolated controls.
[147] Bone mass
[148] Total skeletal bone mass, expressed as total body BMC, was significantly increased by PTH (1-34) (FIG. 3). The vertebral bone mineral density (BMD) remained stable for 18 months in the ovariectomized control and the false control increased approximately 5% above baseline (FIGS. 4A-4C and 5A). rhPTH (1-34) increased spinal BND by 7% to 14% and total bone mineral content (BMC, FIG. 3) increased by 6% relative to baseline (FIGS. 4A-4C and 5A). The bony bone mineral content also increased (FIG. 5A). In rhPTH (1-34) treated primates, these increases were markedly higher than in ovarian isolated controls and matched (PTH1) or exceeded (PTH5) the false group. rhPTH (1-34) did not alter the BMD of the midshaft or distal radius. The cross section of the midshaft was increased by 7% in the PTH5 group. In proximal tibia, cross-sectional area did not increase, but rhPTH (1-34) increased BMC and BMD compared to ovarian isolated controls. After 6 months of treatment, BMD and BMC in the vertebrae and femoral necks maintained higher levels compared to the ovarian-extracted controls and there was no change in the cortical midshaft of the humerus.
[149] Bone strength
[150] rhPTH (1-34) increased the intensity (F _y ) in the vertebrae by 43% (Tables 7 and 8, FIG. 5B). rhPTH (1-34) improved the intensity in the femoral alley (Fu) by 12% (Tables 7 and 9, FIG. 6A). rhPTH (1-34) is a measure of the material properties of beam specimens taken from cortical bony (Tables 7 and 10) or femoral bones of the humerus midshaft (Tables 7 and 9, FIG. 6B) when compared to the ovarian isolated controls. Did not change. Bone strength measurements in animals treated with rhPTH (1-34) for 12 months and withdrawal for 6 months were significantly higher than ovarian extracted controls (Tables 7-10, FIGS. 5A and 6A).
[151] Variables reported in third and fourth lumbar vertebrae (L-3 and L-4), humerus midshaft, proximal femoral alley and femoral beam specimen variableunitExplanation Lumbar spine, L-3 and L-4 Amm ² Cross section F _y NForce obtained is the force at 0.2% offset. SN / mmSlope (stiffness) of the linear portion of the force-travel curve σγMpaObtained stress EMpaYoung's coefficient Humerus Midshaft tmmAverage cortical thickness F _u NUltimate force is the maximum force the specimen can withstand. SN / mmThe slope (stiffness) of the linear portion of the force-travel curve, this is the stiffness. mJ / UN / mmArea under the load transfer curve (U = breakage work) Proximal Femoral Alley F _u NUltimate force is the maximum force the specimen can withstand. Femoral Interbody Beam Specimens σ _u MpaUltimate stress EGpaYoung's coefficient uJ / m ³ tenacity ε _u Ultimate strain
[152] Biomechanical measurement of intensity in the vertebrae (lumbar lumbar L-3 and L-4 combination) of ovarian isolated primates at 18 months Variable (unit) ^a falsehoodOVX controlPTH1PTH1-WPTH5PTH5-W A (mm ² )90.5 ± 2.1 ^b 86.7 ± 2.388.3 ± 2.090.9 ± 2.387.3 ± 2.782.8 ± 2.1 F _y (N)1738 ± 521499 ± 94 ^s 1915 ± 105 ^o 1899 ± 73 ^o 2113 ± 77 ^{s, o} 1792 ± 59 ^oS (N / mm)7312 ± 3195805 ± 476 ^s 7701 ± 474 ^o 7401 ± 452 ^o 8012 ± 367 ^o 7074 ± 314 ^oσ _v (Mpsa)19.4 ± 0.617.3 ± 1.021.9 ± 1.3 ^o 21.1 ± 0.8 ^o 24.6 ± 1.1 ^{s, o} 21.9 ± 0.9 ^oE (Mpa)650 ± 32546 ± 49717 ± 48 ^o 699 ± 42759 ± 36 ^o 698 ± 41 ^oAbbreviation: OVX = ovary extracted; 1 μg / kg rhPTH (1-34) for PTH1 = 18 months; Recovery for 6 months after rhPTH (1-34) 1 μg / kg treatment for PTH1-W = 12 months; PTH5 = 5 μg / kg rhPTH (1-34) for 18 months; PTH5-W = Recovery for 6 months after 5 μg / kg treatment of rhPTH (1-34) for 12 months.a: See Table 4.1 for a description of the variablesb. Expressed as: statistically significant compared to OVX control (p <0.05) s: statistically significant compared to false control (p <0.05)
[153] Biomechanical measurements of the material properties of corresponding size beam specimens from the femoral bones at 18 months, and biomechanical measurements of the strength of the femoral alleys in ovarian isolated primates Variable (unit) ^a falsehoodOVX controlPTH1PTH1-WPTH5PTH5-W σ _u (Mpa)222 ± 5 ^b 216 ± 5222 ± 4214 ± 6206 ± 6208 ± 6 E (Gpa)17.2 ± 0.616.4 ± 0.417.1 ± 0.416.6 ± 0.615.4 ± 0.6 ^s 15.3 ± 0.6 ^bu (mJ / m ³ )5.9 ± 0.35.8 ± 0.46.1 ± 0.45.5 ± 0.45.4 ± 0.46.1 ± 0.4 ε _u 0.035 ± 0.0010.035 ± 0.0020.036 ± 0.0020.034 ± 0.0020.034 ± 0.0020.038 ± 0.002 Proximal Femoral Alley F _u 1288 ± 411105 ± 53 ^s 1235 ± 45 ^o 1258 ± 52 ^o 1362 ± 30 ^o 1213 ± 42 Abbreviation: OVX = ovary extracted; 1 μg / kg rhPTH (1-34) for PTH1 = 18 months; Recovery after rhPTH (1-34) 1 μg / kg treatment for PTH1-W = 12 months; PTH5 = 5 μg / kg rhPTH (1-34) for 18 months; PTH5-W = Recovery after rhPTH (1-34) 5 μg / kg treatment for 12 months a: See Table 4.1 for a description of the variables b: Data expressed as standard deviation of the mean ± mean per group Statistically significant compared to control group (p <0.05) s: Statistically significant compared to false control group (p <0.05)
[154] Biomechanical Measurements of Midshaft Cortical Bone of Primate Humerus Isolated at 18 Months Variable (unit) ^a falsehoodOVX controlPTH1PTH1-WPTH5PTH5-W t (mm)1.74 ± 0.04 ^b 1.63 ± 0.03 ^s 1.68 ± 0.031.66 ± 0.041.80 ± 0.04 ^o 1.72 ± 0.05 F _u (N)725 ± 26636 ± 26654 ± 23689 ± 23680 ± 15 ^s 707 ± 24 S (N / mm)601 ± 23520 ± 26544 ± 23573 ± 20548 ± 18573 ± 24 U (mJ)1797 ± 851542 ± 921641 ± 1371751 ± 841804 ± 991775 ± 113 Abbreviation: OVX = ovary extracted; 1 μg / kg rhPTH (1-34) for PTH1 = 18 months; Recovery after rhPTH (1-34) 1 μg / kg treatment for PTH1-W = 12 months; PTH5 = 5 μg / kg rhPTH (1-34) for 18 months; PTH5-W = Recovery after rhPTH (1-34) 5 μg / kg treatment for 12 months a: See Table 4.1 for a description of the variables b: Data expressed as mean ± standard deviation of mean (SEM) o: OVX control Statistically significant compared to (p <0.05) s: statistically significant compared to false control (p <0.05)
[155] Bone Tissue Morphology Measurement
[156] Metabolic rate was higher for ovarian extraction compared to the false control, but there was no significant loss of bone volume in the iliac crest. Only the static scale was measured at this point because no tetracycline levels were detected in many animals at 6 months. Static and dynamic histomorphologic data at 15 months increased the cavernous bone area compared to ovarian extraction with rhPTH (1-34) treatment, without increasing reuptake measurements beyond that measured in ovarian extracted controls. Increases bone formation. Bone formation rate was gradually increased by high dose rhPTH (1-34). After recovery of rhPTH (1-34) after 12 months of treatment, the spongy bone remained increased compared to the ovarian-extracted control, but bone formation and resorption returned to the Nathan value in the ovarian-extracted control, and the bone metabolic rate was false. It was kept higher than the control. rhPTH (1-34) did not affect mineralization, activation frequency or duration of remodeling. There was no difference in each bone multicellular unit (BMU) -based bone equilibrium between resorption and formation. In summary, rhPTH (1-34) increased spongy bone by selective stimulation of bone formation.
[157] In the cortical bone of the humerus, when rhPTH (1-34) did not significantly alter BMD or bone strength measurements, rhPTH (1-34) stimulated changes in the periosteum, endothelial and intracortical compartments (Tables 11 and 12) . Although there was no difference in total area or Medula area between groups, rhPTH (1-34) increased cortical area, and PTH5 and PTH5-W groups had significantly more cortical bone, which is the moment of inertia of the cross section. Increasing strength measurements are proposed. The increase in area may be due to increased formation at both periosteal and endoscopy surfaces (FIG. 7).
[158] False control and PTH5-W groups reduced periosteal mineralization surface compared to ovarian control and other rhPTH (1-34) treatment groups. Cortical bone mineralization surface was significantly larger in ovarian-extracted controls compared to the false group, and rhPTH (1-34) did not increase above ovarian-extracted controls. In cortical bone remodeling, there was more resorption space in ovarian isolated animals, and activation frequency was greater in the ovarian, PTH1 and PTH5 groups than in the false control or recovery groups. Ovarian-extracted groups had significantly more labeled bone sources per unit area than the false control group, and rhPTH (1-34) did not increase them above the ovarian-extracted control values.
[159] Cortical bone porosity was greater in the ovarian-extracted group than in the false group, but there was no difference between the ovarian-extracted control and PTH1. PTH5 and PTH5-W increased porosity beyond that seen in ovarian isolated controls. The data from the rabbit study suggest the hypothesis that the increase in porosity accompanying the increase in cortical bone may be a structural response to maintain the biomechanical properties of rhPTH (1-34) treated bone. There was no difference in duration of formation, bone source width, wall thickness, or bone maturation between the ovarian and other groups at 18 months.
[160] In summary, there was no difference in metabolic rate between ovarian extracted controls and rhPTH (1-34) administration groups. False control had lower metabolic rate than ovarian control or rhPTH (1-34) -treated animals. When rhPTH (1-34) was recovered for 6 months, metabolic rate decreased significantly but BMD and biomechanical strength measurements remained higher than ovarian extracted controls. For all groups intracortically, normal values of bone width and maturation time indicate that treatment did not result in any defects in the normal timing of the mineralization process. Normal values of wall width indicate that treatment does not change the normal balance between resorption and formation at the level of individual BMUs.
[161] Histomorphologic Parameters for Cortical Bone Measurement of Humerus Variable ^a unitExplanation Ac.FCycles / yearActivation frequency BFR / BS.EcΜm / dayBone formation rate, intracortical surface object BFR / BS.PsΜm / dayBone formation rate, periosteal surface targets BFR / BV%/yearBone Formation Rate, Bone Volume Target FPWorkForming period L.On.N / Ct.A# / mmNumber of fluorescently labeled bone sources per unit cortical area MARΜm / dayMineral adhesion rate, intracortical bone MAR.EcΜm / dayMineral adhesion rate, intracortical surface MAR.PsΜm / dayMineral adhesion rate, periosteal surface MS / BS.Ec%Inorganicized cortical surfaces standardized to total cortical surfaces MS / BS.Ps%Mineralized Periosteal Surface Standardized to Total Periosteum Surface O.WiΜmAshes width Rs.N / Ct.A# / mmNumber of reabsorbed spaces per unit cortical area W.WiΜmAsh wall width omtWorkAshes maturation time Po%Porosity, percentage of bone area occupied by space B.Armm ² Bone area, total area within the periosteum surface Ct.Armm ² Cortical area, bone area within the periosteal surface (including pores) Mc.armm ² Course area a name is recommended in the Journal of Bone and Mineral Research, 1987.
[162] Cortical bone histology of the humeral midshaft of primates isolated at 18 months (n = 121) Variable ^a falsehoodOVXPTH1PTH1-WPTH5PTH5-W Ac.F1.85 ± 1.87 ^{a, c} 6.06 ± 3.317.69 ± 4.963.05 ± 2.15 ^a 8.70 ± 3.972.05 ± 1.46 ^aBFR / BS.Ec7.08 ± 3.8020.93 ± 19.2318.14 ± 13.9514.89 ± 10.3234.04 ± 19.0112.73 ± 16.33 ^aBFR / BS.Ps3.79 ± 3.079.12 ± 7.588.53 ± 10.543.60 ± 3.84 ^a 8.99 ± 5.815.79 ± 4.05 BFR / BV2.13 ± 2.06 ^a 9.16 ± 5.379.23 ± 5.934.39 ± 3.48 ^a 12.93 ± 5.94 ^a 2.21 ± 1.73 ^aFP82.73 ± 41.0665.94 ± 19.7963.44 ± 10.0264.94 ± 11.9981.97 ± 95.6388.63 ± 52.90 L.On.N / Ct.A0.28 ± 0.27 ^a 1.03 ± 0.521.26 ± 0.710.50 ± 0.36 ^a 1.45 ± 0.47 ^a 0.38 ± 0.26 ^aMAR0.91 ± 0.33 ^a 1.07 ± 0.190.98 ± 0.12 ^a 1.06 ± 0.271.03 ± 0.230.85 ± 0.28 ^aMAR.Ec0.48 ± 0.19 ^a 0.75 ± 0.250.66 ± 0.150.66 ± 0.160.75 ± 0.140.63 ± 0.17 MAR.PS0.62 ± 0.240.69 ± 0.230.89 ± 0.950.54 ± 0.15 ^a 0.66 ± 0.170.82 ± 0.15 MS / BS.Ec3.09 ± 6.49 ^a 20.99 ± 18.0425.19 ± 17.1411.74 ± 14.41 ^a 40.47 ± 24.68 ^a 8.93 ± 15.39 ^aMS / BS.Ps1.81 ± 3.59 ^a 10.03 ± 10.498.59 ± 5.733.86 ± 4.83 ^a 11.00 ± 9.632.30 ± 3.76 ^aO.Wi3.77 ± 0.924.04 ± 0.913.66 ± 0.673.96 ± 0.833.94 ± 1.133.76 ± 0.83 Rs.N / Ct.A0.12 ± 0.17 ^a 0.21 ± 0.130.28 ± 0.180.12 ± 0.07 ^a 0.43 ± 0.26 ^a 0.19 ± 0.18 W.Wi63.23 ± 13.6168.63 ± 15.0961.36 ± 7.7963.12 ± 17.3565.28 ± 9.4363.82 ± 8.31 omt4.58 ± 1.26 ^a 3.87 ± 1.043.76 ± 0.703.86 ± 0.746.45 ± 13.855.07 ± 2.65 Po1.32 ± 0.60 ^a 2.61 ± 1.404.65 ± 4.782.23 ± 1.606.78 ± 4.23 ^a 6.40 ± 4.22 ^aB.Ar53.12 ± 5.5052.82 ± 7.0954.22 ± 5.9754.94 ± 6.5555.81 ± 6.2458.16 ± 8.79 ^aCt.Ar37.40 ± 3.7535.35 ± 5.0437.61 ± 3.8638.10 ± 4.8340.96 ± 4.30 ^a 40.83 ± 5.80 ^aMe.Ar15.72 ± 4.0717.47 ± 4.2216.61 ± 3.7716.84 ± 3.7414.85 ± 4.72 ^a 17.34 ± 6.05 Abbreviation: OVX = ovary extracted; 1 μg / kg rhPTH (1-34) for PTH1 = 18 months; Recovery after rhPTH (1-34) 1 μg / kg treatment for PTH1-W = 12 months; PTH5 = 5 μg / kg rhPTH (1-34) for 18 months; PTH5-W = Recovery after rhPTH (1-34) 5 μg / kg treatment for 12 months. A: Statistically significant compared to OVX control (p <0.05) b: See Table 4.2 for a description of the variables c: Data Is the mean ± standard deviation of the mean (SEM)
[163] Analysis by histomorphometry and polarized Fourier transform infrared microscopy revealed that administration of PTH improved bone quality by replacing older bones (large crystals) with younger bones (range of classified crystals with smaller size trends). . Moreover, the recovery of PTH from low dose monkeys has the additional advantage that the matrix is optimally mineralized and the crystals mature. Data derived from histomorphometry and Fourier transform infrared microscopy show the unexpected advantage of maturing minerals with optimal mineralization of bone material in the cortical bone.
[164] 3D Constraint Modeling Study
[165] Experiments on intermediate 500 μm pieces of L-5 resulted in a 21% increase in BMD due to a 27% increase in BMC with no change in cross-sectional area for PTH compared to ovarian extraction. Central analysis from PTH showed a 30% increase in Tb.Th and a 37% increase in BV / TV due to a 37% increase in Tb.N compared to ovarian extraction. Binding analysis at this site showed nodule density (nodule / tissue volume) of at least 140% and nodule versus nodule struts for PTH vertebrae.
[166] Analysis of histogram distribution of bone volume pixel density for PTH showed a decrease in the ratio of low density (0-355 mg / cc), an increase in medium density (356-880 mg / cc), and high density volume compared to ovarian extraction. The pixel (887-1200 mg / cc) showed little effect (FIG. 8). Most surprising was the conversion from the cortical bone compartment to greater bone volumetric density after 6 months of treatment (FIG. 8).
[167] The proportion of vertebral elements (volume pixels) within a specific range of BMD values was calculated. The selected BMD range was as follows: low BMD, 0-300 mg / cc; Medium BMD, 300-700 mg / cc; High BMD, 700-1000 mg / cc; And cortical BMD,> 1000 mg / cc (Table 13). PTH treatment significantly reduced the volume of low BMD bones and significantly increased the volume of intermediate BMD bones when compared to ovarian isolated controls. After recovery of PTH, the intermediate BMD bones decreased and the high BMD bones decreased, indicating that the intermediate BMD bones became more dense.
[168] Percentage of L5 bone volume classified by BMD value (mean ± SEM) processLow BMD (%)Medium BMD (%)High BMD (%)Cortical BMD (%) Ovarian Extraction30.4 ± 2.248.7 ± 1.619.9 ± 1.20.9 ± 0.3 PTH17.7 ± 1.6 *58.9 ± 1.9 *22.8 ± 2.70.6 ± 0.3 PTH-W22.4 ± 1.3 *49.7 ± 1.227.0 ± 1.6 *0.8 ± 0.2
[169] BMC and vertebral effective stress at the median level of L5 vertebrae processBMC (mg)Effective stress Ovarian Extraction37.2 ± 1.6701 ± 64 PTH47.4 ± 1.5 *447 ± 36 * PTH-W44.2 ± 1.2 *539 ± 34 * Statistically different (p <0.05 by Fisher PLSD test)
[170] The data summarized in FIG. 8 shows bone mass, small bone thickness and small bone bonding with L-5 vertebrae derived from cyanomolgus monkeys treated with PTH for 18 months, with a minor effect on the external size (X-area) of the vertebrae. Responds to a significant increase in Analysis of the distribution of bone elements at L-5 showed that the heavily inorganicized bone sites change at least without signs of osteosclerosis. Rather, the most responsive to PTH was the porous shochu bone. The change in BMD results in a substantial reduction in axial stress, which indicates a mechanical improvement. As is apparent from the histograms of PTH and ovarian extracted BMD, PTH transformed low-density bone bulk pixels into medium-density bulk pixels without significant effect on high-density bulk pixels.
[171] The data summarized in Table 2 shows that BMC was significantly increased throughout the midbone by PTH treatment, and the beneficial effect of PTH remained 6 months after recovery. The average mechanical stress in the vertebrae was reduced by 36% by PTH treatment and remained below OVX 23% after recovery of PTH. This study indicates that recovery of PTH treatment for 6 months did not result in reabsorption of newly formed bones, but instead there was a beneficial redistribution of medium density bones into low and high density bones. This redistribution resulted in continued stress reduction in the vertebra and thus improved mechanical action.
[172] Review
[173] This primate study indicates that in the absence of other medications that may affect bone, a given PTH increases the total skeletal bone mass, benefiting both the cortical bone and the small bone. Moreover, the recovery of PTH does not result in significant loss of benefits associated with PTH treatment over a period of two or more rebuild cycles.
[174] Alternative markers were used in other attempts to indicate activity in bone, and these were assumed to change in value to reflect changes in bone mass. For example, there are published data on humans and primates that indicate an increase in both formation and reuptake markers consistent with activation of bone metabolic rate during early menopause or active disease states, but high metabolic turnover is thought to indicate bone loss. do. In puberty, high metabolic rate during maturation of the human skeleton has not been well studied, but is accompanied by anabolic gains in bone mass. This phenomenon has never been foreseen in the current pharmacotherapy of osteoporosis. Thus, the increase in bone metabolic rate markers is inconsistent with the known anabolic effects of PTH on increasing bone mass and strength as shown in the data in this study.
[175] Data from this 18 month study on cynomolgus monkeys supports the following unexpected findings.
[176] Overall significant increase in total skeletal mass
[177] Significant increase in bone mass and strength in the femoral alleys
[178] No evidence of "steal" from the cortical bone to increase the small bone. The increase in bone mass and strength is statistically significant at sites rich in cortical bone (femoral condyle) or small bone (lumbar bone). In the pure cortical bone area (intermedial femur bone), PTH tended to stabilize or somewhat increase bone mass and strength compared to the ovarian isolated control group.
[179] Changes in bone markers in ovarian monkeys (and humans) did not reflect the beneficial anabolic effects of PTH on the skeleton. The use of primate-derived body fluids in this study enables the development of new and more relevant surrogate markers.
[180] Maintenance of gain in bone mass and strength for at least two remodeling cycles after the number of treatments.
[181] This PTH primate study differs from published studies on rhesus and cynomolgus monkeys in that large sample sizes are used to provide adequate statistical power to detect differences that may not be apparent in earlier studies. Different, controls include ovarian extracted primates (used in published studies) and false worked but intact primates. Since the latter control was not reported in this type of previous study, the recovery of certain specific values for false control levels was first assessed compared to some of the benefits of PTH and values for ovarian isolated animals.
[182] conclusion
[183] This 18-month study in mature, femoral, ovarian cyst (OVX) cynomolgus monkey macaque pasculolaris was followed by 6 months of treatment or 18 months after 12 months of treatment with rhPTH (1-34). For the treatment of the bones to ensure the efficacy and stability. rhPTH (1-34) significantly increased bone mass and strength in the vertebral and femoral bones to levels above or above the ovarian control group and to those corresponding to or above the false control group. In ovarian isolated monkeys treated with rhPTH (1-34), measurements of calcium homeostasis (serum calcium, phosphate and 1,25-dihydroxyvitamin D) were restored to the case of false control. Serum, urine, and histomorphologic measurements used to assess bone metabolic rate indicate that rhPTH (1-34) maintains a rate of formation corresponding to or higher than that of ovarian-extracted controls, while biochemical bioreactivity of bone resorption is achieved. The marker shows that it remained corresponding to the case of the false control. In all animals treated with rhPTH (1-34) for 18 months, pharmacodynamic measurements did not change over time and there was no accumulation of rhPTH (1-34). There was no evidence that hypercalcemia or kidney pathology was supported 18 months after treatment. There was no change in the duration of mineralization or reformation. The net gain in skeletal bone mineral content observed in rhPTH (1-34) can be explained by the bone formation surface with little or no effect on increased bone formation rate and bone resorption. Measurements of bone mineral content, bone mineral density and biomechanical strength, including toughness and stiffness, have significantly increased in clinically relevant areas such as the spine, femoral alley and proximal tibia.
[184] rhPTH (1-34) increased metabolic turnover in the cortical bone of the midshaft of the humerus and radial as compared to the ovarian or false control, but did not significantly alter the measurements of bone mass or biomechanical strength. However, an increase in cortical bone width and / or cortical bone area is consistent with an increase in measurements of moment of inertia, strength and stiffness of the cross section. rhPTH (1-34) had no significant effect on the intrinsic material properties of the cortical bone. Intracortical bone formation was stimulated to increase cortical bone width and intracortical bone porosity. These changes in porosity have been shown to play a role in maintaining bone elasticity.
[185] In monkeys, a six-month recovery following 12-month treatment of rPTH (1-34) was associated with smaller but still significant gains in bone mass and strength in the vertebrae or femurs. Following recovery, no significant effect was noted on the cortical midshaft of the humerus or radius. Bone markers and histomorphometry showed a tendency to revert to the low metabolic rate measured in the false control.
[186] In vivo mechanical studies in rodents indicated that genes involved in the assimilation of rhPTH (1-34) were upregulated in 1 to 6 hours, and an increase in bone formation surface was observed 24 hours after the first dose without appreciable effect on resorption. It has been shown that it can be detected within. rhPTH (1-34) has been shown to rapidly increase the percentage of bone formation surface by supplementing bone precursor cells on S- and promoting differentiation into osteoblasts. Single or multiple infusions of rhPTH (1-34) may be given within a one hour period to induce anabolic effects in bone. However, when the dose was given as multiple infusions over 6 or 8 hours in young rats, the anabolic effect was discarded, suggesting that a short limited exposure to rhPTH (1-34) is required to induce an assimilation effect. do.
[187] In summary, rhPTH (1-34) is anabolic on bone in monkeys and rats, increasing bone mass and biomechanical strength measurements by selective stimulation of bone formation at clinically relevant sites such as lumbar and femoral bones. Increases in bone metabolic rate, intracortical surface formation, and porosity detected by histomorphometry at cortical bone sites did not alter biomechanical measures of bone mass or bone strength, but increased cross-sectional inertia by increasing cortical bone area and / or width. Moment increased.
[188] These studies show that parathyroid hormone receptor activators such as recombinant human PTH (1-34) improve bone quality both during and after treatment. In fact, a one-day PTH administration for 18 months, or a six-month recovery period following the same administration for 12 months, resulted in a significant improvement in the cortical bone quality of the humerus in analysis by histomorphometry or polarized Fourier transform infrared (FTIR) microscopy. Improvement was shown. This analysis shows that PTH administration improved bone quality by replacing older bones (large crystals) with younger bones (classified crystal ranges of smaller size trends). Thus, administration of PTH can increase cortical bone quality, improve mineralization, and accelerate mineralization and replacement of old bone with new bone.
[189] Moreover, upon the recovery of PTH from a given low dose monkey, there is an additional advantage that the matrix is more optimally mineralized and the crystals mature. That is, at low doses, PTH may have the added benefit of recovery time of treatment by enhancing mineralization. These data indicate the benefit of limited prescription of payback period following PTH treatment to achieve enhanced benefits. The current definition of bone quality does not include these aspects of improved mineralization.
[190] In the initial study at the time of no treatment followed by PTH, the treatment time was less than 1 month. Two or more remodeling cycles following extended but limited treatment of 18-24 months have not been studied previously. The continued benefits in primates after the number of treatments are significant compared to the results achieved in rodents administered PTH. Studies in mice have consistently shown that bone is rapidly lost after the number of treatments (Gunness-Hey, M. and Hock, JM (1989) Bone 10: 447-452; Shen, V. et al. (1993) J. Clin Invest 91: 2479-2487; Shen, V. et al. (1992) Calcif.Tissue Int. 50: 214-220; and Mosekilde, L. et al. (1997) Bone 20: 429-437).
[191] This method of improving bone mineralization has not been observed before, and unexpectedly reveals new ways PTH can strengthen and strengthen bones and prevent fractures. These new methods include strengthening and regulating mineralization to provide stronger, stronger and more fracture resistant bones. This beneficial effect requires more than new matrix formation. These findings also indicate that PTH is beneficial in patients with fixed bones or skeletons or in skeletons deficient in minerals, provided adequate calcium and vitamin D supplementation is provided.
[192] <Example 3>
[193] Increased bone strength and density and reduced fractures when rhPTH (1-34) is administered to humans
[194] Target countrhPTH (1-34): 1093 registered, 848 finished Placebo: 544 registered, 447 finished Diagnostic and Inclusion CriteriaWomen aged 30 to 85 years of menopause for at least 5 years with at least one moderate or two mild nontraumatic vertebral fractures Dosage and Method of AdministrationExperimental product (blind) rhPTH (1-34): 20 μg / day, transdermal infusion rhPTH (1-34): 40 μg / day, transdermal injection control (blank) Treatment periodrhPTH (1-34): 17 to 23 months (excluding 6 months of preparation) Placebo: 17 to 23 months (excluding 6 months of preparation) Evaluation standardSpinal X-rays; Serum biological markers (calcium, bone specific alkaline phosphatase, procollagen I carboxy-terminal propeptide); Urine markers (calcium, N-telopeptide, free deoxypyridinolin); 1,25-dihydroxyvitamin D; Bone mineral density; Spine, gluteal, radial and total body weight; kidney; Group pharmacodynamics; Bone Necropsy (Selected Research Site)
[195] Patient characteristics
[196] Placebo (N = 544)PTH-20 (N = 541)PTH-40 (N = 552)p-value Caucasus age postmenopausal uterine hysterectomy uterus + 0 or 1 ovarian arch + 2 osteoporosis drug use baseline before ovarian unknown baseline spine BMD baseline vert.fx # 01234567891098.9% 69.0 ± 7.020.9 ± 8.523.8% 57611114.9% 0.82 ± 0.1754 (10.4%) 144 (27.8%) 128 (24.7%) 75 (14.5%) 59 (11.4%) 28 (5.4%) 13 (2.5% ) 6 (1.2%) 9 (1.7%) 1 (0.2%) 1 (0.2%) 2698.9% 69.0 ± 7.121.5 ± 8.723.1% 51571715.5% 0.82 ± 0.1745 (8.8%) 159 (31.1%) 128 (25.0%) 67 (13.1%) 49 (9.6%) 31 (6.1%) 20 (3.9% ) 7 (1.4%) 5 (1.0%) 01 (0.2%) 2998.4% 69.9 ± 6.821.8 ± 8.221.6% 58511013.0% 0.82 ± 0.1754 (10.1%) 169 (31.6%) 125 (23.4%) 81 (15.1%) 45 (8.4%) 21 (3.9%) 25 (4.7% ) 10 (1.9%) 3 (0.6%) 2 (0.4%) 0170.6720.0990.2730.6820.479> 0.990> 0.990
[197] result
[198] These clinical trials included a total of 1637 women treated with recombinant human parathyroid hormone (1-34), rhPTH (1-34) 0, 20 or 40 μg / kg / day and supplemented with vitamin D and calcium for 18 to 24 months. The data from shows the results reported in Tables 15-19.
[199] Table 15 describes data indicating a reduction in the number and severity of vertebral fractures during PTH treatment. Comparing all PTH treated patients to placebo, the overall reduction in the number of vertebral fractures in the patients was 67% (p <0.001) and 65% reduction in 20 μg / day PTH (p <0.001) and There was a 69% reduction in 40 μg / day PTH (Table 15). Comparing all PTH treated patients with placebo, the overall reduction in the number of multiple vertebral fractures in the patient was 81% (p <0.001) and 77% reduction in 20 μg / day PTH compared to placebo (p <0.001) And a 86% reduction in 40 μg / day PTH. Comparing all PTH treated patients with placebo, the overall reduction in the number of patients with moderate to severe vertebral fractures was 84% (p <0.001) and 90% reduction in 20 μg / day PTH compared to placebo (p <0.001). ), And a 78% reduction in 40 μg / day PTH (Table 15).
[200] Effect of PTH Treatment on the Number and Severity of the Fractures of the BonePlacebo (n * = 448)20 μg / day PTH (n = 444)40 μg / day PTH (n = 434) Number and percentage of patients with new bone fractures64 (14.3%)22 (5.0%)19 (4.4%) Number and percentage of patients with two or more new bone fractures22 (4.9%)5 (1.1%)3 (0.7%) Number and percentage of patients with moderate to severe new bone fractures **42 (9.4%)4 (0.9%)9 (2.1%) * n = number of patients with both baseline and endpoint x-rays ** Intermediate fractures result in loss of the vertebral height (or equivalent) of 25% or more. Severe fractures result in a loss of bone height (or equivalent) of more than 40%. Fracture is defined by Genand et al. (1993) (Vertebral fracture assessment using a semiquantitative technique; J. Bone & Min Res 81137-1148).
[201] Table 16 describes the effects of PTH treatment on the number of fractures in various nasal bones throughout the body. The number of fractures was clearly reduced in the gluteal, radial, coronal, humerus, rib, foot, pelvis and other areas, respectively (Table 16). The reduction is statistically significant when looking at the reduction in the total number of fractures in the PTH treated patients compared to the placebo treated patients. The reduction is more significant given the reduction in the total number of gluteal, radial, coronal, humerus, rib, foot and pelvic fractures among PTH treated patients compared to placebo treated patients (Table 16).
[202] Effect of PTH Treatment on the Number of Lumbar Fractures p-valuePlacebo (N = 544)PTH-20 (N = 541)PTH-40 (N = 552)allPTH-pbo *20-pbo40-pbo Glutes4230.7180.4740.4170.690 radius137100.4040.2360.1800.504 zygoma4220.6010.3130.4170.403 Humerus5430.7670.5340.7440.465 rib10550.2770.1090.1970.184 foot4One40.3740.4740.1810.983 pelvis3One00.1710.0760.3190.081 Etc161490.3380.2960.7230.146 gun5334320.0240.0070.0360.015 Total w / o "other"4121240.0130.0030.0100.025 Placebo (pbo)
[203] The effect of PTH on bone mineral content (BMC), bone mineral density (BMD) and bone area was measured using a dual energy absorption meter (DEXA) and the results are reported in Tables 17-19. PTH administration resulted in a clear increase in BMC in the lumbar spine, femur and gluteal of the patient, the knee joint and the entire body of the patient (Table 17). Treatment of PTH significantly increased the BMD of the patient in the lumbar spine, femur and gluteal (Table 18). The increase in lumbar spine, femur and gluteal was statistically significant with p <0.001 (Table 18). In the lumbar spine, femur and gluteal of the patient, the bone area was obviously increased upon PTH treatment (Table 19). The increase was statistically significant for lumbar and gluteal bones (Table 19).
[204] Of particular importance are the overall body measurements of bone quantity and quality and the effect of PTH on BMC. This systemic effect indicates an increase in the amount of bone in the patient's body. PTH does not only result in the movement of bone mass from one part of the patient's body to another. Instead, PTH treatment increases the amount and quality of bone in the patient's body.
[205] 9 and 10 illustrate the time-dependent increase in lumbar BMD and femur / gluteus neck BMD for PTH treated and placebo control patients, respectively. The lumbar BMD of the patient increases steadily for more than about 18 months, then there is no increase or minor increase. The patient's femur / fusal BMD is clearly increased for at least 18 months and may increase during further PTH treatment.
[206] Effect of PTH on Bone Mineral Content, expressed as% End Point Change (SD) from BaselinePlaceboPTH-20PTH-40p-value Lumbar vertebra1.60 (6.92)11.85 (8.83)16.62 (11.1)<0.001 Femur / Gluteus pelvis-0.38 (5.18) -0.51 (7.06) 0.98 (14.97) -0.23 (6.28) 0.01 (14.75)3.50 (6.26) 2.99 (7.26) 5.58 (15.58) 3.59 (7.32) 5.36 (14.78)4.78 (6.70) 5.80 (8.71) 6.53 (15.33) 4.99 (7.79) 8.86 (17.02)<0.001 <0.001 <0.001 <0.001 <0.001 Knee joint distal 1/3-1.67 (7.44) -1.19 (6.12)-0.25 (6.53) -1.37 (4.51)-1.88 (7.97) -3.04 (6.09)0.1840.025 all-0.74 (4.76)1.30 (4.48)2.28 (5.44)<0.001
[207] Effect of PTH on Bone Mineral Density as Percent Change of End Point (SD) from BaselinePlaceboPTH-20PTH-40p-value Lumbar vertebra1.13 (5.47)9.70 (7.41)13.7 (9.69)<0.001 Femur / Gluteus pelvis-1.01 (4.25) -0.69 (5.39) -0.21 (6.30) -1.29 (4.53) -0.80 (11.73)2.58 (4.88) 2.79 (5.72) 3.50 (6.81) 2.62 (5.52) 4.19 (11.93)3.60 (5.42) 5.06 (6.73) 4.40 (7.45) 3.98 (5.96) 7.85 (13.24)<0.001 <0.001 <0.001 <0.001 <0.001 Knee joint distal 1/3-1.89 (7.98) -1.22 (3.37)-0.05 (7.14) -1.94 (4.07)-1.76 (7.20) -3.17 (4.62)0.1080.001
[208] Effect of PTH on Bone Area as End Point Percent Change (SD) from BaselinePlaceboPTH-20PTH-40p-value Lumbar vertebra0.46 (2.97)2.52 (3.52)3.34 (3.72)<0.001 Femur / Gluteus pelvis0.54 (3.02) 0.04 (4.60) 0.95 (12.75) 1.01 (5.17) 0.44 (7.60)0.84 (3.16) 0.27 (4.91) 1.99 (12.16) 1.01 (4.99) 1.13 (7.34)1.05 (2.98) 0.81 (5.56) 1.92 (11.30) 1.01 (4.89) 0.99 (8.06)0.1440.0350.1970.9640.309 Knee joint distal 1/30.25 (6.40) -0.02 (5.73)-0.25 (6.00) 0.52 (3.40)-0.39 (4.80) 0.01 (4.42)0.6530.586
[209] In summary, the data presented above indicate a reduction in fractures in PTH treated patients. In particular, PTH treatment reduced the number of patients with previous fractures of the new fractures by more than 66%. In addition, PTH treatment reduced the number of patients with previous fractures of the fractures with new multiple vertebral fractures by more than 78%. In addition, PTH reduced the severity of vertebral fractures with a significant reduction of 78% of the number of patients with moderate or severe fractures. Patients receiving PTH have the advantage that all non-vertebral fractures (including fractures of the hip bone, radial bone, knee joint, pelvis, foot, humerus, rib or bone) are significantly reduced to a significant level of p <0.007. Bone quality also increases. Earlier fracture patients benefit from a significant increase in the bone mineral content of the gluteus, vertebrae and total body. This increase indicates that fracture reduction at these sites can occur as early as 12 months after treatment.
[210] Review
[211] These data for fractures are the first data of fracture reduction by PTH in humans. This finding demonstrates an improvement in bone quality and bone strength, similar to the preclinical data reported above. These results also indicate an advantage in bone quality and strength in the nasal bones. The discovery of a reduction in the number of fractures maintained for 18 to 23 months of treatment was not observed in previous clinical or preclinical studies.
[212] The question of whether PTH alone can increase bone toughness and strength to improve fracture resistance has not been previously tested in humans. The published literature consistently suggested that PTH should be given in anti-resorption methods or in combination with estrogen. The previously published clinical trials could not determine a significant reduction in fractures, including too small patient populations. In one study, the benefits of PTH alone could not be evaluated because there was no placebo control. In the second study, fracture reduction was not observed using the commonly accepted definition of fracture.
[213] The discovery of fracture reduction in the combined bony site is not particularly predicted in terms of general belief that PTH has a negative effect at such sites. It was the general orthodox that PTH would increase cortical porosity and thus weaken bones, especially at the beginning of treatment. Moreover, this orthodoxy argued that the cortical bone site was a high fracture risk site and that PTH would not provide any benefit in reducing fracture at the non-bulb site. It also asserted that PTH alone would not be effective and would need to be combined with anti-resorptive therapy to block negative effects on cortical bone. This data demonstrates the previously unobserved benefits of PTH given to patients receiving vitamin D and calcium supplementation. Unexpectedly, PTH strengthens bones, reducing the number of new fractures in patients at risk of multiple fractures of the spine, risk of additional non-vertebral fractures, and additional to moderate fractures of the spine.
[214] This clinical study in postmenopausal women shows that the dose of PTH (which may have side effects in some patients at high doses) is reduced, but fracture prevention and fracture reduction are similar to those mentioned at higher doses (40 μg / day). As such, it has shown particular advantages in treating patients at low dosages (20 μg / day). FT-IR monkey data provide mechanism explanations that are possible but not limited to. Monkey studies show that low dose PTH increases crystal formation and promotes mineralization in the cortical bone. In addition, low dose monkeys have shown additional benefits after recovery, such as PTH improves the mineral content of bone. This data demonstrates that PTH given at low doses in patients receiving vitamin D and calcium supplementation is effective in preventing fractures of both the vertebra and the vertebrae. Contrary to popular belief, PTH reinforces bone at the site of the bony bone, significantly improving the mineralization and mineral content of the bone, preventing new fractures or reducing the severity of fractures.
[215] The present invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made within the spirit and scope of the invention. All documents and patent applications herein are directed to the general level of skill in the art to which this invention belongs.

权利要求:
Claims (59)
[1" claim-type="Currently amended] A method of increasing bone toughness or stiffness at a potential or actual traumatic site of a subject, comprising administering an effective amount of parathyroid hormone to the subject in need thereof.
[2" claim-type="Currently amended] The method of claim 1, wherein the trauma is a potential trauma comprising a fracture, a surgical operation, or an orthopedic procedure involving the handling of bone at an abnormally low bone mass or poor bone structure site.
[3" claim-type="Currently amended] The method of claim 2, wherein the surgical operation is joint replacement, chiropractic, or a combination thereof.
[4" claim-type="Currently amended] 4. The method of claim 3, wherein the joint replacement comprises gluteal replacement.
[5" claim-type="Currently amended] The method of claim 2, wherein the fracture comprises a vertebral fracture, a vertebral fracture, or a combination thereof.
[6" claim-type="Currently amended] 7. The method of claim 6, wherein the vertebral fracture includes a hip fracture, a distal forearm fracture, a proximal humerus fracture, a shoulder fracture, a radial fracture, a bone fracture, a humerus fracture, a rib fracture, a foot fracture, a pelvic fracture, or a combination thereof. Way.
[7" claim-type="Currently amended] The method of claim 1, wherein the trauma is a potential trauma involving trauma related to the progression of parathyroid hypoplasia or scoliosis.
[8" claim-type="Currently amended] The method of claim 1, wherein the trauma is a real trauma including a fracture.
[9" claim-type="Currently amended] The method of claim 8, wherein the fracture comprises a vertebral fracture, a vertebral fracture, or a combination thereof.
[10" claim-type="Currently amended] 10. The method of claim 9, wherein the vertebral fracture includes a hip fracture, a distal forearm fracture, a proximal humerus fracture, a shoulder fracture, a radial fracture, a bone fracture, a humerus fracture, a rib fracture, a foot fracture, a pelvic fracture, or a combination thereof. Way.
[11" claim-type="Currently amended] The method of claim 1 wherein said bone comprises a fixed bone or skeleton, a bone or skeleton lacking minerals, or a combination thereof.
[12" claim-type="Currently amended] The method of claim 1, wherein the bone comprises cortical bone, spongy bone, soju bone, or a combination thereof.
[13" claim-type="Currently amended] The method of claim 12, wherein the bone comprises a site of attachment to ligaments, tendons, muscles, or a combination thereof.
[14" claim-type="Currently amended] The method of claim 1, wherein the trauma site is a gluteal vertebrae, spine, or a combination thereof.
[15" claim-type="Currently amended] The method of claim 14, wherein the traumatic site comprises a femoral alley, a femur of a femur, an iliac bone, or a combination thereof.
[16" claim-type="Currently amended] 16. The method of claim 15, wherein the trauma site comprises the cavernous bone of the iliac bone.
[17" claim-type="Currently amended] The method of claim 14, wherein the trauma site comprises a central thoracic bone, an upper lumbar bone, or a combination thereof.
[18" claim-type="Currently amended] The method of claim 1, wherein the subject is a woman at risk for osteoporosis.
[19" claim-type="Currently amended] The method of claim 18, wherein the subject is a postmenopausal woman.
[20" claim-type="Currently amended] 20. The method of claim 19, wherein said woman is independent of hormone replacement therapy or anti-absorption therapy.
[21" claim-type="Currently amended] The method of claim 1, wherein the subject is a woman in the early stages of osteoporosis or the progression of osteoporosis.
[22" claim-type="Currently amended] The method of claim 1 wherein the increase in toughness or stiffness comprises an increase in toughness and stiffness.
[23" claim-type="Currently amended] The method of claim 1, wherein said increasing toughness or stiffness comprises reducing the risk or likelihood of fracture.
[24" claim-type="Currently amended] The method of claim 1, wherein the increase in toughness or stiffness comprises increasing the frequency of activation or rate of bone formation in the cortical bone and the osseous bone.
[25" claim-type="Currently amended] The method according to claim 1, wherein the increase in toughness or rigidity is characterized by an increase in bone mineral content, an increase in bone mineral density, an increase in the count of bone minerals, an increase in the thickness of the bone mineral bones, a decrease in the bone marrow space, an increase in the degree of bone mineral bonding, and the binding. Increased degrees, increased load tolerance, increased periosteal and intracortical bone formation, increased cortical porosity, increased bone cross-sectional area and bone mass, increased work to failure, reduced modulus of elasticity, or combinations thereof How to include.
[26" claim-type="Currently amended] The method of claim 1, wherein said administering comprises transdermal administration.
[27" claim-type="Currently amended] The method of claim 1, wherein the parathyroid hormone is administered periodically or intermittently.
[28" claim-type="Currently amended] The method of claim 27, wherein said periodic administration comprises administering parathyroid hormone during at least two remodeling cycles and recovering parathyroid hormone during at least one remodeling cycle.
[29" claim-type="Currently amended] The method of claim 27, wherein the periodic administration comprises administering parathyroid hormone for at least about 12 to about 24 months and recovering parathyroid hormone for at least 6 months.
[30" claim-type="Currently amended] According to claim 1, wherein the parathyroid hormone is selected from the group consisting of PTH (1-31), PTH (1-34), PTH (1-37), PTH (1-38) and PTH (1-41) Method that is a fragment hormone.
[31" claim-type="Currently amended] The method of claim 1, wherein said parathyroid hormone is human PTH (1-34).
[32" claim-type="Currently amended] The method of claim 1, wherein said parathyroid hormone is human PTH (1-84).
[33" claim-type="Currently amended] The method of claim 1, wherein the parathyroid hormone is administered at a dose of about 5 μg / kg / day or more.
[34" claim-type="Currently amended] The method of claim 33, wherein the dose is about 10 to about 40 μg / kg / day.
[35" claim-type="Currently amended] The method of claim 1 further comprising administering calcium, vitamin D, or a combination thereof.
[36" claim-type="Currently amended] The method of claim 1, wherein the increasing toughness or stiffness comprises increasing the bone mineral content of the medium density bone.
[37" claim-type="Currently amended] The method of claim 1, wherein the increase in toughness or stiffness comprises increasing bone mineral content of low and high density bones and reducing bone mineral content of medium density bones.
[38" claim-type="Currently amended] The method of claim 1, wherein the increase in toughness or stiffness comprises increasing the bone mineral content of the medium density bone, and then increasing the bone mineral content of the low density and high density bone and reducing the bone mineral content of the medium density bone. .
[39" claim-type="Currently amended] The method of claim 1 wherein said increasing toughness or stiffness comprises reducing the size of a crystal of bone.
[40" claim-type="Currently amended] 40. The method of claim 39 further comprising maturing the crystals of the bone.
[41" claim-type="Currently amended] The method of claim 1, wherein said increasing toughness or stiffness comprises increasing mineralization of bone.
[42" claim-type="Currently amended] The method of claim 1, wherein said increasing toughness or stiffness comprises reducing the occurrence of fracture.
[43" claim-type="Currently amended] 43. The method of claim 42, wherein the increase in toughness or stiffness comprises a reduced incidence of a vertebral fracture, a reduced incidence of a severe fracture, a reduced incidence of an intermediate fracture, a reduced incidence of a non-vertebral fracture, a reduced incidence of multiple fractures, or a combination thereof. How to.
[44" claim-type="Currently amended] A method of reducing the risk of bone fracture in a subject, comprising administering an effective amount of parathyroid hormone to the subject in need thereof.
[45" claim-type="Currently amended] 45. The method of claim 44, wherein the bone comprises the gluteal bone, the radial bone, the tibia, the humerus, the ribs, the foot, the pelvis, the spine, or a combination thereof.
[46" claim-type="Currently amended] 45. The method of claim 44, wherein said parathyroid hormone is selected from the group consisting of PTH (1-31), PTH (1-34), PTH (1-37), PTH (1-38), and PTH (1-41). Method that is a fragment hormone.
[47" claim-type="Currently amended] 45. The method of claim 44, wherein the fracture comprises a vertebral fracture, a vertebral fracture, or a combination thereof.
[48" claim-type="Currently amended] 48. The method of claim 47, wherein the vertebral fracture includes a hip fracture, a distal forearm fracture, a proximal humerus fracture, a shoulder fracture, a radial fracture, a bone fracture, a humerus fracture, a rib fracture, a foot fracture, a pelvic fracture, or a combination thereof. Way.
[49" claim-type="Currently amended] A method of making a medicament for use in increasing the toughness or rigidity of bone at a potential or actual traumatic site, comprising combining parathyroid hormone with a pharmaceutically acceptable carrier.
[50" claim-type="Currently amended] The method of claim 49, wherein the medicament comprises a stabilized formulation of parathyroid hormone.
[51" claim-type="Currently amended] 51. The method of claim 50, wherein the stabilized formulation is
Therapeutically effective amount of parathyroid hormone,
Polyols, such as mannitol or propylene glycol,
Buffers such as acetate or tartrate sources suitable for maintaining the pH of the composition in the range of about 3-7, and
water
How to include.
[52" claim-type="Currently amended] Use of parathyroid hormone in the manufacture of a medicament for reducing the risk of bone fracture in a subject in need.
[53" claim-type="Currently amended] The method of claim 52, wherein the bone comprises the gluteal bone, radial bone, tibia, rib, foot, pelvis, spine, or a combination thereof.
[54" claim-type="Currently amended] 53. The method of claim 52, wherein said parathyroid hormone is selected from the group consisting of PTH (1-31), PTH (1-34), PTH (1-37), PTH (1-38) and PTH (1-41). Method that is a fragment hormone.
[55" claim-type="Currently amended] 53. The method of claim 52, wherein the fracture comprises a vertebral fracture, a vertebral fracture or a combination thereof.
[56" claim-type="Currently amended] 56. The fracture according to claim 55, wherein the vertebral fracture includes a hip fracture, a distal forearm fracture, a proximal humerus fracture, a shoulder fracture, a radial fracture, a osteotomy fracture, a humerus fracture, a rib fracture, a foot fracture, a pelvic fracture, or a combination thereof. Way.
[57" claim-type="Currently amended] Use of parathyroid hormone for the preparation of a composition used to reduce the risk of bone fracture in a subject in need.
[58" claim-type="Currently amended] Use of parathyroid hormone in the manufacture of a medicament for increasing the toughness or rigidity of bone at a potential or actual traumatic site.
[59" claim-type="Currently amended] Use of parathyroid hormone to prepare a composition used to increase the toughness or stiffness of bone at a potential or actual traumatic site.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BENNETT et al.1984|Insulin-like growth factors I and II: aging and bone density in women

---

TAM et al.1982|Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration

---

Riggs1991|Overview of osteoporosis.

---

Wada et al.1998|NPS R-568 halts or reverses osteitis fibrosa in uremic rats

---

Namkung-Matthai et al.2001|Osteoporosis influences the early period of fracture healing in a rat osteoporotic model

---

Uebelhart et al.1995|Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review

---

Cornish et al.2002|Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo

---

Hodsman et al.2005|Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use

---

Gabet et al.2004|Osteogenic growth peptide modulates fracture callus structural and mechanical properties

---

Tuck et al.2009|Testosterone, bone and osteoporosis

---

Dahl et al.2001|Incorporation and distribution of strontium in bone

---

Longhino et al.2011|The management of sacral stress fractures: current concepts

---

Fujita et al.1999|Effect of an intermittent weekly dose of human parathyroid hormone | on osteoporosis: a randomized double-masked prospective study using three dose levels

---

Jerome et al.2001|Treatment with human parathyroid hormone | for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys |

---

Ammann et al.1996|Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats

---

Lala et al.2000|Pamidronate treatment of bone fibrous dysplasia in nine children with McCune‐Albright syndrome

---

Rubin et al.2003|The anabolic effects of parathyroid hormone therapy

---

Compston2007|Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure

---

US7776826B2|2010-08-17|Method for fostering bone formation and preservation

---

Blick et al.2008|Teriparatide

---

JP3053116B2|2000-06-19|Pharmaceutical composition

---

VanHouten et al.2003|Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice

---

Rehman et al.2003|Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis

---

Muñoz-Torres et al.2004|Calcitonin therapy in osteoporosis

---

Vandeweghe et al.1993|Short and long‐term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone‐deficient males

同族专利:

---

公开号 | 公开日

---

CY1113343T1|2016-06-22|

---

ES2549551T3|2017-11-27|

---

JP2017190332A|2017-10-19|

---

DK1769804T3|2012-10-15|

---

EP1059933B1|2003-01-15|

---

EP1059933A1|2000-12-20|

---

EA200001015A1|2001-02-26|

---

NO20072983L|2000-11-24|

---

IL138829D0|2001-10-31|

---

BR9909445A|2000-12-12|

---

NO20005947D0|2000-11-24|

---

ES2393200T3|2012-12-19|

---

PT2907522T|2017-10-23|

---

EP2266598B1|2017-02-22|

---

JP6177718B2|2017-08-09|

---

US6977077B1|2005-12-20|

---

US20050197294A1|2005-09-08|

---

NZ507056A|2003-10-31|

---

NO323984B1|2007-07-30|

---

CA2325371A1|2000-03-02|

---

EA003362B1|2003-04-24|

---

HU0101594A2|2001-11-28|

---

JP2015028065A|2015-02-12|

---

CY1119552T1|2018-03-07|

---

KR100454207B1|2004-10-26|

---

HK1102496A1|2013-08-02|

---

CN1205997C|2005-06-15|

---

PE20001089A1|2000-11-04|

---

DE69904918T2|2003-11-13|

---

WO2000010596A1|2000-03-02|

---

HRP20000755A2|2001-02-28|

---

EP2266598A1|2010-12-29|

---

AU5575099A|2000-03-14|

---

PT2266598T|2017-05-02|

---

ID29039A|2001-07-26|

---

IL138829A|2011-01-31|

---

DK2266598T3|2017-05-15|

---

ES2549551T1|2015-10-29|

---

JP2014139220A|2014-07-31|

---

CZ301017B6|2009-10-14|

---

EP2907522B1|2017-08-02|

---

DE69904918D1|2003-02-20|

---

CZ20004134A3|2001-08-15|

---

JP2011021035A|2011-02-03|

---

DK2907522T1|2015-10-19|

---

JP2002523375A|2002-07-30|

---

US7163684B2|2007-01-16|

---

AU746277B2|2002-04-18|

---

HU0101594A3|2002-01-28|

---

CN1308545A|2001-08-15|

---

HU230697B1|2017-09-28|

---

AT231000T|2003-02-15|

---

ES2621653T3|2017-07-04|

---

AR033639A1|2004-01-07|

---

CO5130020A1|2002-02-27|

---

ES2190244T3|2003-07-16|

---

PT1769804E|2012-11-13|

---

MY129227A|2007-03-30|

---

DZ2873A1|2003-12-15|

---

EP2907522A1|2015-08-19|

---

PL201688B1|2009-04-30|

---

HK1030545A1|2003-07-11|

---

DE15152726T1|2015-12-10|

---

PL343595A1|2001-08-27|

---

TW576747B|2004-02-21|

---

DK2907522T3|2017-10-23|

---

TR200003455T2|2001-06-21|

---

DK1059933T3|2003-04-07|

---

CA2325371C|2004-08-17|

---

NO20005947L|2000-11-24|

---

PT1059933E|2003-06-30|

---

HK1212602A1|2016-06-17|

---

HU1200430D0|2001-11-28|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1998-08-19|Priority to US9715198P

---

1998-08-19|Priority to US60/097,151

---

1998-09-10|Priority to US9974698P

---

1998-09-10|Priority to US60/099,746

---

1999-08-19|Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니

---

2000-09-07|First worldwide family litigation filed

---

2001-07-31|Publication of KR20010072763A

---

2004-10-26|Application granted

---

2004-10-26|Publication of KR100454207B1

优先权:

---

申请号 | 申请日 | 专利标题

---

US9715198P| true| 1998-08-19|1998-08-19|

---

US60/097,151|1998-08-19|

---

US9974698P| true| 1998-09-10|1998-09-10|

---

US60/099,746|1998-09-10|